Clinical Trials

Bio-equivalency Study of Moxifloxacin Tablets, 400 mg Under Fasting Conditions

Condition:   Healthy
Intervention:   Drug: Moxifloxacin Tablets 400 mg
Sponsor:   Dr. Reddy's Laboratories Limited
Completed

Tue, 23 Dec 2014 12:00:00 EST

Moxifloxacin in Situ Gel to Treat Periodontal Pocket.

Condition:   Chronic Generalized Periodontitis
Intervention:   Drug: Moxifloxacin
Sponsor:   Sri Hasanamba Dental College and Hospital
Completed

Thu, 19 Dec 2013 12:00:00 EST

Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis

Condition:   Endophthalmitis
Intervention:   Drug: Moxifloxacin
Sponsor:   Universidade Federal de Pernambuco
Completed

Tue, 03 Nov 2015 12:00:00 EST

Evaluation of Efficacy and Safety of Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis.

Condition:   Endophthalmitis
Interventions:   Drug: Moxifloxacin;   Drug: No injection of moxifloxacin
Sponsor:   University of Campinas, Brazil
Terminated

Thu, 12 May 2016 12:00:00 EDT

A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg

Condition:   Chronic Obstructive Pulmonary Disease
Interventions:   Drug: Zabofloxacin;   Drug: Moxifloxacin
Sponsors:   Dong Wha Pharmaceutical Co. Ltd.;   Chonbuk National University Hospital;   Chosun University Hospital;   Bundang CHA Hospital;   Chungbuk National University;   Kangdong Sacred Heart Hospital;   Hanyang University;   Asan Medical Center;   Gachon University Gil Medical Center;   The Catholic University of Korea;   Konyang University Hospital;   KangWon National University Hospital;   Gyeongsang National University Hospital;   Kyunghee University Medical Center;   Korea University Anam Hospital;   DongGuk University;   Severance Hospital;   Yeungnam University Hospital;   Ulsan University Hospital;   Ewha Womans University Mokdong Hospital;   Inje University;   Chonnam National University Hospital;   Catholic University of Korea Saint Paul's Hospital;   Incheon St.Mary's Hospital;   Masan Samsung Hospital, South Korea;   Konkuk University Medical Center;   Keimyung University Dongsan Medical Center;   Wonju Severance Christian Hospital;   Hallym University Medical Center;   Ajou University;   Chungnam National University Hospital
Completed

Mon, 06 Aug 2012 12:00:00 EDT

The Effect of Ethnic on Moxifloxacin Induced QT Interval Prolongation in Korean and Japanese Healthy Subjects

Condition:   Healthy
Interventions:   Drug: Moxifloxacin;   Drug: Placebo
Sponsor:   Inje University
Completed

Wed, 12 Jun 2013 12:00:00 EDT

Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)

Conditions:   Bacterial Pneumonia;   Community-Acquired Infections
Interventions:   Drug: Omadacycline;   Drug: Moxifloxacin
Sponsor:   Paratek Pharmaceuticals Inc
Completed

Mon, 24 Aug 2015 12:00:00 EDT

Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess

Condition:   Liver Abscess
Interventions:   Drug: Moxifloxacin (Avelox);   Drug: ceftriaxone
Sponsors:   Kaohsiung Veterans General Hospital.;   Bayer
Completed

Thu, 07 May 2009 12:00:00 EDT

Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia

Conditions:   Community-acquired Pneumonia;   Bacterial Pneumonia
Interventions:   Drug: Omadacycline;   Drug: Moxifloxacin
Sponsor:   Paratek Pharmaceuticals Inc
Recruiting

Wed, 03 Mar 2021 12:00:00 EST

Bioequivalence Study of Mofest® 400mg (Moxifloxacin) Tablet With Avelox® 400mg (Moxifloxacin) Tablet in Healthy Pakistani Subjects

Conditions:   Healthy Individuals;   Bioequivalence Study
Intervention:   Drug: Moxifloxacin 400mg
Sponsors:   University of Karachi;   SAMI Pharmaceutical, Karachi Pakistan;   Center for Bioequivalence Studies and Clinical Research
Completed

Wed, 05 May 2021 12:00:00 EDT

Genetics of QT Response to Moxifloxacin

Condition:   Cardiac Arrhythmias
Interventions:   Drug: Moxifloxacin 400mg once time;   Drug: Placebo
Sponsor:   Massachusetts General Hospital
Unknown status

Fri, 06 Sep 2013 12:00:00 EDT

Vigamox Treatment for Ocular Graft-Versus-Host Disease

Condition:   Ocular Graft-versus-host Disease
Interventions:   Drug: Vigamox;   Drug: Placebo
Sponsor:   Washington University School of Medicine
Recruiting

Wed, 18 Dec 2019 12:00:00 EST

Penetration of Moxifloxacin Into Liver Tissue of Patients Undergoing Liver Resection.

Condition:   Side-effect of Antibiotic
Intervention:   Drug: Moxifloxacin 400 mg
Sponsors:   University Hospital, Saarland;   Bayer
Completed

Thu, 24 Feb 2011 12:00:00 EST

Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia

Condition:   Community Acquired Pneumonia
Interventions:   Drug: lefamulin;   Drug: Moxifloxacin
Sponsor:   Nabriva Therapeutics AG
Completed

Mon, 27 Jun 2016 12:00:00 EDT

VICTOR - Avelox® Intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis

Conditions:   Chronic Bronchitis;   Disease Exacerbation
Intervention:   Drug: Moxifloxacin (Avelox, BAY12-8039)
Sponsor:   Bayer
Completed

Mon, 06 Apr 2009 12:00:00 EDT

Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

Condition:   Community-acquired Bacterial Pneumonia
Interventions:   Drug: Solithromycin;   Drug: Moxifloxacin
Sponsor:   Melinta Therapeutics, Inc.
Completed

Thu, 24 Oct 2013 12:00:00 EDT

Evaluation of Macular Changes After Intracameral Moxifloxacin for Prevention of Endophthalmitis

Conditions:   Endophthalmitis;   Macula Edema;   Cataract
Intervention:   Drug: Moxifloxacin Injection
Sponsor:   Universidade Federal de Pernambuco
Completed

Wed, 06 Dec 2017 12:00:00 EST

Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia

Condition:   Community-Acquired Bacterial Pneumonia (CABP)
Interventions:   Drug: JNJ-32729463;   Drug: moxifloxacin;   Drug: JNJ-32729463 (Open-Label)
Sponsor:   Furiex Pharmaceuticals, Inc
Terminated

Fri, 10 Sep 2010 12:00:00 EDT

Moxifloxacin_QT Study in Chinese Healthy Volunteer

Condition:   QT Interval Prolongation
Interventions:   Drug: moxifloxacin;   Drug: moxifloxacin-placebo
Sponsor:   Peking University Third Hospital
Unknown status

Tue, 31 Jul 2012 12:00:00 EDT

Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis

Condition:   Tuberculosis
Intervention:   Drug: Moxifloxacin
Sponsor:   Johns Hopkins University
Completed

Tue, 04 May 2004 12:00:00 EDT

Effect of Glucose on QTc Interval in Type 1 Diabetes

Condition:   Diabetes
Interventions:   Drug: Moxifloxacin;   Other: hyper-glycaemic clamp
Sponsors:   Richmond Research Institute;   Richmond Pharmacology Limited
Completed

Fri, 15 Nov 2013 12:00:00 EST

Greatest International Antiinfective Trial With Avelox

Conditions:   Bronchitis, Chronic;   Bronchial Diseases
Intervention:   Drug: Moxifloxacin (Avelox, BAY12-8039)
Sponsor:   Bayer
Completed

Fri, 03 Jul 2009 12:00:00 EDT

Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis

Condition:   Tuberculosis
Interventions:   Drug: Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid;   Drug: Isoniazid, Rifampin, Pyrazinamide, Ethambutol
Sponsors:   Johns Hopkins University;   Universidade Federal do Rio de Janeiro
Terminated

Tue, 05 Aug 2008 12:00:00 EDT

Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients

Condition:   TB
Intervention:   Drug: levofloxacin, moxifloxacin
Sponsor:   Seoul National University Hospital
Terminated

Mon, 25 Jan 2010 12:00:00 EST

Efficacy of Moxifloxacin/Prednisolone in Prevention of Post Surgery Inflammation

Condition:   Eye Infection/Inflammation Other
Interventions:   Drug: moxifloxacin 0,5% + prednisolone 1%;   Drug: moxifloxacin/prednisolone combination
Sponsor:   Adapt Produtos Oftalmológicos Ltda.
Unknown status

Tue, 22 May 2012 12:00:00 EDT

Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells

Conditions:   Hodgkin Disease;   Non-Hodgkin Lymphoma;   Multiple Myeloma;   Bacteremia
Interventions:   Drug: moxifloxacin;   Drug: placebo
Sponsor:   University of Cologne
Completed

Fri, 10 Nov 2006 12:00:00 EST

Safety and Efficacy Study of DAV132 in Healthy Volunteers

Condition:   Healthy
Interventions:   Device: DAV132;   Drug: Moxifloxacin;   Other: Negative Control
Sponsor:   Da Volterra
Completed

Thu, 26 Jun 2014 12:00:00 EDT

Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

Condition:   Community-acquired Bacterial Pneumonia
Interventions:   Drug: Solithromycin;   Drug: Moxifloxacin;   Other: Placebo to match solithromycin
Sponsor:   Melinta Therapeutics, Inc.
Completed

Tue, 25 Dec 2012 12:00:00 EST

Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia

Condition:   Community Acquired Pneumonia
Interventions:   Drug: Moxifloxacin;   Drug: Ampicillin;Amoxicillin
Sponsors:   University of Ulm;   CAPNETZ Stiftung
Terminated

Thu, 23 Apr 2009 12:00:00 EDT

The Clinical Safety of Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%

Condition:   Endophthalmitis Postoperative
Interventions:   Drug: Levofloxacin Ophthalmic Product;   Drug: Moxifloxacin Ophthalmic Solution
Sponsors:   National University of Malaysia;   Santen Pharmaceutical Co., Ltd.
Recruiting

Fri, 27 Dec 2019 12:00:00 EST

AVANTI - Avelox® in Acute Exacerbations of chroNic bronchiTIs

Condition:   Bronchitis, Chronic
Intervention:   Drug: Moxifloxacin (Avelox, BAY12-8039)
Sponsor:   Bayer
Completed

Thu, 19 Feb 2009 12:00:00 EST

Comparison of Moxifloxacin With Ciprofloxacin/Metronidazole on Patients With Chronic Periodontitis

Condition:   Chronic Periodontitis
Interventions:   Drug: moxifloxacin;   Drug: Ciprofloxacin plus metronidazole
Sponsors:   Facultad Nacional de Salud Publica;   Universidad de Antioquia
Completed

Tue, 09 Dec 2008 12:00:00 EST

Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification

Condition:   Cataracts
Interventions:   Drug: Moxifloxacin;   Drug: besifloxacin
Sponsor:   Frank A. Bucci, Jr., M.D.
Completed

Tue, 15 Feb 2011 12:00:00 EST

CAPRIVI: Community Acquired Pneumonia: Treatment With Avelox® in Hospitalized Patients

Condition:   Pneumonia
Intervention:   Drug: Moxifloxacin (Avelox, BAY12-8039)
Sponsor:   Bayer
Completed

Thu, 01 Oct 2009 12:00:00 EDT

Efficacy and Safety of Isoniazid, Rifampicin and Moxifloxacin for the Intensive Phase of Initial Therapy of PTB

Condition:   Pulmonary Tuberculosis
Interventions:   Drug: Moxifloxacin, Isoniazid, Rifampicin;   Drug: Rifampicin,Isoniazid,Pyrazinamide,Ethambutol
Sponsor:   Fifth Affiliated Hospital, Sun Yat-Sen University
Not yet recruiting

Thu, 05 Dec 2019 12:00:00 EST

A Study Study to Investigate the Effect on QT/QTc Interval of Moxifloxacin After a Single Dose in Healthy Male Subjects

Condition:   the Effect of Moxifloxacin on QT/QTc Interval
Intervention:   Drug: Moxifloxacin
Sponsors:   Seoul National University Hospital;   Korea National Enterprise for Clinical Trials;   The Catholic University of Korea;   Seoul National University Bundang Hospital
Completed

Thu, 27 Dec 2012 12:00:00 EST

The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%

Condition:   Endophthalmitis
Interventions:   Drug: Levofloxacin Ophthalmic Solution;   Drug: Moxifloxacin Ophthalmic Solution
Sponsors:   National University of Malaysia;   Santen Pharmaceutical Co., Ltd.
Recruiting

Thu, 02 Jan 2020 12:00:00 EST

A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers

Condition:   Solid Tumors
Interventions:   Drug: AZD6094 200 mg;   Other: Placebo;   Drug: Moxifloxacin
Sponsors:   AstraZeneca;   Parexel
Completed

Wed, 23 Aug 2017 12:00:00 EDT

Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)

Conditions:   Secondary Peritonitis;   Abscess, Intra-Abdominal
Intervention:   Drug: Moxifloxacin (Avelox, BAY12-8039)
Sponsor:   Bayer
Completed

Wed, 31 Mar 2010 12:00:00 EDT

Pharmacokinetic Evaluation of Moxifloxacin IV to Enteral Switch Therapy in Intensive Care Patients

Condition:   Pneumonia
Intervention:   Drug: IV and enteral administration of moxifloxacin
Sponsor:   University Hospital, Ghent
Completed

Wed, 11 Apr 2007 12:00:00 EDT

Pharmacokinetics and Safety of Moxifloxacin

Condition:   Tuberculosis
Intervention:   Drug: Moxifloxacin
Sponsor:   University Medical Center Groningen
Terminated

Tue, 05 Apr 2011 12:00:00 EDT

QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo

Condition:   Healthy
Interventions:   Drug: MAP0004;   Drug: Inhaler Placebo;   Drug: Moxifloxacin;   Drug: Placebo Capsule
Sponsors:   Allergan;   MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
Completed

Tue, 31 Aug 2010 12:00:00 EDT

To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects

Condition:   Nausea and Vomiting, Chemotherapy-Induced
Interventions:   Drug: ondansetron;   Drug: moxifloxacin;   Other: saline
Sponsor:   GlaxoSmithKline
Completed

Mon, 10 Oct 2011 12:00:00 EDT

Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer

Conditions:   Advanced Breast Cancer;   Antibiotic;   Stable Disease With a Trend of Progression
Intervention:   Drug: Moxifloxacin Hydrochloride 400mg Tablet
Sponsor:   Sun Yat-sen University
Completed

Fri, 19 Jan 2018 12:00:00 EST

Effect on Wound Healing of Vigamox Versus Cravit

Condition:   Cataract Extraction
Interventions:   Drug: Moxifloxacin 0.5% ophthalmic solution (Vigamox);   Drug: Levofloxacin 0.5% ophthalmic solution (Cravit)
Sponsor:   Alcon Research
Completed

Tue, 10 Feb 2009 12:00:00 EST

Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox

Condition:   Maxillary Sinusitis
Intervention:   Drug: Avelox (Moxifloxacin, BAY12-8039)
Sponsor:   Bayer
Completed

Tue, 29 Apr 2008 12:00:00 EDT

Race Difference Moxifloxacin-induced QT Prolongation Between Healthy Chinese and Caucasian Volunteers

Condition:   Cardiac Toxicity
Intervention:   Drug: Moxifloxacin
Sponsors:   Haiyan Li;   Food and Drug Administration (FDA);   Spaulding Clinical Research LLC;   BioClinica, Inc.;   Peking University
Unknown status

Mon, 21 Apr 2014 12:00:00 EDT

Avelox in Complicated Skin and Skin Structure Infections

Condition:   Skin Diseases, Bacterial
Intervention:   Drug: Moxifloxacin (Avelox, BAY12-8039)
Sponsor:   Bayer
Completed

Tue, 20 Oct 2009 12:00:00 EDT

Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem

Condition:   Infection
Interventions:   Drug: Moxifloxacin (Avelox, BAY12-8039);   Drug: Ertapenem intravenous
Sponsor:   Bayer
Completed

Wed, 27 Jun 2007 12:00:00 EDT

Pharmacokinetic Evaluation of Moxifloxacin Administered Intravenously and Orally in Healthy Volunteers Who Have Had a Gastric Bypass

Conditions:   Gastric Bypass;   Body Weight
Interventions:   Drug: moxifloxacin per IV;   Drug: moxifloxacin per os
Sponsor:   University Ghent
Completed

Wed, 26 May 2010 12:00:00 EDT

A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease

Condition:   Pelvic Inflammatory Disease
Interventions:   Drug: Moxifloxacin (Avelox, BAY12-8039);   Drug: Levofloxacin & Metronidazole
Sponsor:   Bayer
Completed

Wed, 28 Mar 2007 12:00:00 EDT

Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections

Condition:   Intravitreal Injection Patients
Intervention:   Drug: Vigamox
Sponsors:   Illinois Retina Associates;   Alcon Research
Completed

Wed, 04 Jun 2008 12:00:00 EDT

BAY12-8039: 5 Days for Sinusitis vs Placebo

Condition:   Sinusitis
Interventions:   Drug: Moxifloxacin (Avelox, BAY12-8039);   Drug: Placebo
Sponsor:   Bayer
Completed

Wed, 27 Jun 2007 12:00:00 EDT

An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients

Condition:   Bacterial Conjunctivitis
Interventions:   Drug: Moxifloxacin ophthalmic solution, 0.5%;   Drug: Ofloxacin ophthalmic solution, 0.3%
Sponsor:   Alcon Research
Completed

Tue, 10 Apr 2012 12:00:00 EDT

Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors

Condition:   Community-Acquired Pneumonia
Interventions:   Drug: moxifloxacin;   Drug: levofloxacin;   Drug: metronidazole
Sponsor:   Beijing Hospital
Unknown status

Tue, 16 Sep 2008 12:00:00 EDT

Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia

Condition:   Community Acquired Pneumonia
Interventions:   Drug: lefamulin;   Drug: Moxifloxacin;   Drug: Linezolid
Sponsor:   Nabriva Therapeutics AG
Completed

Thu, 24 Sep 2015 12:00:00 EDT

Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers

Conditions:   Bacterial Infections;   Eye Infections
Interventions:   Drug: Azithromycin;   Drug: Moxifloxacin
Sponsor:   Merck Sharp & Dohme Corp.
Completed

Wed, 28 Nov 2007 12:00:00 EST

Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients

Condition:   Infections
Intervention:   Drug: Moxifloxacin (Avelox, BAY12-8039)
Sponsor:   Bayer
Completed

Thu, 14 Jan 2010 12:00:00 EST

Study to Evaluate the Efficacy and Safety of Moxifloxacin Versus Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Rhinosinusitis

Conditions:   Sinusitis;   Bacterial Infections
Interventions:   Drug: Moxifloxacin (Avelox, BAY12-8039);   Drug: Amoxicillin/Clavulanate
Sponsor:   Bayer
Terminated

Wed, 27 Jun 2007 12:00:00 EDT

Adjunctive Systemic Administration of Moxifloxacin in the Treatment of Aggressive Periodontitis

Condition:   Aggressive Periodontitis
Interventions:   Other: scaling and systemic moxifloxacin;   Other: scaling and root planing
Sponsors:   Facultad Nacional de Salud Publica;   Universidad de Antioquia
Completed

Tue, 29 Apr 2014 12:00:00 EDT

Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers

Condition:   Tuberculosis
Interventions:   Drug: Moxifloxacin;   Drug: PA-824;   Other: Placebo
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Completed

Tue, 28 Aug 2012 12:00:00 EDT

Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine

Condition:   Mycobacterium Tuberculosis
Interventions:   Drug: Moxifloxacin;   Drug: Rifapentine
Sponsor:   Johns Hopkins University
Terminated

Mon, 16 Apr 2007 12:00:00 EDT

Improving Retreatment Success (IMPRESS)

Condition:   Recurrent Tuberculosis
Intervention:   Drug: moxifloxacin
Sponsor:   Centre for the AIDS Programme of Research in South Africa
Completed

Tue, 15 Apr 2014 12:00:00 EDT

Comparisons of Intravenous Ceftriaxone With Intravenous Moxifloxacin in ERCP

Condition:   Cholangitis
Interventions:   Drug: Moxifloxacin;   Drug: ceftriaxone
Sponsor:   Kangbuk Samsung Hospital
Completed

Fri, 28 Mar 2014 12:00:00 EDT

To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart

Conditions:   Chronic Obstructive Pulmonary Disease;   Lung Disease
Interventions:   Drug: AZD3199;   Drug: Moxifloxacin;   Other: Placebo comparator
Sponsor:   AstraZeneca
Completed

Mon, 18 Oct 2010 12:00:00 EDT

Effect of Moxifloxacin Versus Gatifloxacin on Corneal Epithelium Following Pterygium Excision

Condition:   Primary Pterygium
Intervention:   Drug: Moxifloxacin ophthalmic solution 0.5% ; Gatifloxacin ophthalmic solution 0.3%
Sponsor:   Meir Medical Center
Unknown status

Tue, 05 May 2009 12:00:00 EDT

Study to Assess Cardiac Conduction of GSK1349572

Condition:   Healthy Subjects
Interventions:   Drug: GSK1349572 250 mg;   Drug: Placebo Suspension;   Drug: Moxifloxacin 400 mg
Sponsors:   GlaxoSmithKline;   Shionogi
Completed

Fri, 16 Oct 2009 12:00:00 EDT

Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection

Conditions:   Abscess;   Wound Infection;   Diabetic Foot;   Ulcer
Interventions:   Drug: Moxifloxacin (Avelox, BAY12-8039);   Drug: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid
Sponsor:   Bayer
Completed

Wed, 22 Nov 2006 12:00:00 EST

To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers

Condition:   Solid Tumours
Interventions:   Drug: Selumetinib;   Drug: Moxifloxacin;   Drug: selumetinib placebo
Sponsor:   AstraZeneca
Completed

Thu, 06 Feb 2014 12:00:00 EST

The Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets on QT /QTc Intervals in Healthy Adult Subjects

Condition:   Healthy
Interventions:   Drug: HYD;   Drug: Moxifloxacin;   Drug: Placebo for HYD;   Drug: Placebo for moxifloxacin
Sponsor:   Purdue Pharma LP
Completed

Wed, 17 Sep 2014 12:00:00 EDT

Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer

Condition:   Triple Negative Breast Cancer
Interventions:   Drug: Gemcitabine and carboplatin plus antibiotic (moxifloxacin);   Drug: Gemcitabine combined with carboplatin plus placebo
Sponsor:   Sun Yat-sen University
Recruiting

Mon, 25 Jan 2021 12:00:00 EST

Postoperative Safety Outcomes of Intraoperative Intracameral Preservative-Free Moxifloxacin Versus Levofloxacin

Conditions:   Cataract Senile;   Endophthalmitis;   Antibiotic Side Effect;   Safety Issues
Interventions:   Drug: Levofloxacin Ophthalmic;   Drug: Moxifloxacin Ophthalmic
Sponsor:   Peregrine Eye and Laser Institute
Completed

Wed, 27 May 2020 12:00:00 EDT

Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia

Condition:   Community Acquired Bacterial Pneumonia
Interventions:   Drug: Delafloxacin;   Drug: Moxifloxacin;   Drug: Linezolid
Sponsor:   Melinta Therapeutics, Inc.
Completed

Wed, 10 Feb 2016 12:00:00 EST

2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery

Conditions:   Corneal Health;   Cataract Surgery
Interventions:   Drug: besivance;   Drug: vigamox
Sponsors:   Ophthalmology Consultants, Ltd.;   Ophthalmology Associates, St Louis;   Bausch & Lomb Incorporated
Completed

Wed, 19 Oct 2011 12:00:00 EDT

Treatment of Mycobacterium Xenopi Pulmonary Infection

Condition:   Atypical; Mycobacterium, Pulmonary, Tuberculous
Interventions:   Drug: Clarithromycin;   Drug: Moxifloxacin
Sponsor:   Centre Hospitalier Universitaire, Amiens
Completed

Thu, 17 Feb 2011 12:00:00 EST

Antibiotic or Not in Non-purulent Exacerbations of COPD: a Trial of Security and Efficacy

Condition:   Chronic Obstructive Pulmonary Disease
Intervention:   Drug: Moxifloxacin
Sponsors:   Fundacion Clinic per a la Recerca Biomédica;   Instituto de Salud Carlos III
Completed

Wed, 24 Mar 2010 12:00:00 EDT

Bioequivalence of Eye Drops and Spray Administration of Vigamox

Condition:   Cataract
Interventions:   Drug: Vigamox - administration in spray form;   Drug: Vigamox eye drops
Sponsor:   Advanced Ophthalmic Pharma
Completed

Thu, 24 Apr 2008 12:00:00 EDT

Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia

Condition:   Pneumonia
Interventions:   Drug: Avelox (Moxifloxacin, BAY12-8039);   Drug: Levofloxacin
Sponsor:   Bayer
Completed

Wed, 23 Apr 2008 12:00:00 EDT

Intensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study

Conditions:   Meningitis, Tuberculous;   Pharmacokinetics;   Pharmacodynamics;   Tolerability
Intervention:   Drug: Moxifloxacin
Sponsors:   Universitas Padjadjaran;   Radboud University
Completed

Thu, 08 Jul 2010 12:00:00 EDT

Effects of Single Oral Dose Dapagliflozin QT Study

Condition:   Healthy
Interventions:   Drug: Dapagliflozin;   Drug: Moxifloxacin;   Drug: Placebo to match moxifloxacin and dapagliflozin
Sponsors:   AstraZeneca;   Bristol-Myers Squibb
Completed

Tue, 03 Jun 2008 12:00:00 EDT

Phase 1 Study to Assess the Effects of EVP-6124 on the QT/QTc Interval in Healthy Subjects

Conditions:   Healthy Subjects;   Cardiac Repolarization
Interventions:   Drug: EVP-6124;   Drug: Placebo;   Drug: Moxifloxacin
Sponsors:   FORUM Pharmaceuticals Inc;   Quintiles, Inc.
Completed

Wed, 07 Dec 2011 12:00:00 EST

TQT2 Study to Evaluate the Effect of MD1003 on Cardiac Repolarization in Healthy Adult Subjects

Condition:   Healthy Volunteers
Interventions:   Drug: MD1003;   Drug: Moxifloxacin 400mg;   Drug: Placebo for MD1003;   Drug: Placebo for moxifloxacin
Sponsors:   MedDay Pharmaceuticals SA;   Parexel;   ERT: Clinical Trial Technology Solutions
Recruiting

Tue, 19 Nov 2019 12:00:00 EST

A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)

Condition:   Healthy
Interventions:   Drug: JNJ-64565111;   Drug: Moxifloxacin;   Drug: JNJ-64565111-matching Placebo;   Drug: Moxifloxacin-matching Placebo
Sponsor:   Janssen Research & Development, LLC
Completed

Mon, 30 Jul 2018 12:00:00 EDT

Influence of Moxifloxacin on QTc Interval in Healthy Subjects for Positive Control Validation

Conditions:   QTc Evaluation;   Electrocardiography
Interventions:   Drug: Avelox (Moxifloxacin, BAY12-8039);   Drug: Placebo
Sponsor:   Bayer
Completed

Mon, 16 Nov 2009 12:00:00 EST

Food and Insulin Effect on QT/QTC Interval of ECG

Conditions:   Effects of Different Meals on the QT/QTc Interval;   Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use;   C-Peptide Effects on the QT/QTc Interval;   Moxifloxacin ECG Profile in Fed and Fasted State;   Japanese vs. Caucasian TQT Comparison
Interventions:   Drug: Moxifloxacin 400 mg fasted;   Other: FDA breakfast;   Other: Continental breakfast;   Drug: Moxifloxacin 400 mg fed;   Procedure: Insulin Clamp;   Drug: Placebo
Sponsor:   Richmond Pharmacology Limited
Completed

Tue, 17 Jul 2012 12:00:00 EDT

Ocular Penetration of 1.5% Levofloxacin and 0.5% Moxifloxacin During Corneal Transplant Surgery

Condition:   Corneal Transplantation
Interventions:   Drug: 1.5% levofloxacin ophthalmic solution;   Drug: 0.5% moxifloxacin ophthalmic solution
Sponsors:   Santen Inc.;   Vistakon Pharmaceuticals
Terminated

Thu, 02 Oct 2008 12:00:00 EDT

Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart

Condition:   Healthy Male
Interventions:   Drug: TC-5214;   Other: Placebo comparator;   Drug: Moxifloxacin;   Other: Moxifloxacin placebo comparator
Sponsor:   AstraZeneca
Terminated

Wed, 25 May 2011 12:00:00 EDT

AL-15469A for the Treatment of Bacterial Conjunctivitis

Condition:   Bacterial Conjunctivitis
Interventions:   Drug: Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%;   Drug: Moxifloxacin hydrochloride ophthalmic solution 0.5% as base
Sponsor:   Alcon Research
Completed

Thu, 01 Jun 2006 12:00:00 EDT

Comparison of Two Antibiotic Regimen (Meropenem Versus Meropenem+Moxifloxacin)in the Treatment of Severe Sepsis and Septic Shock

Conditions:   Severe Sepsis;   Septic Shock
Interventions:   Drug: meropenem;   Drug: meropenem, moxifloxacin
Sponsors:   Kompetenznetz Sepsis;   AstraZeneca;   Bayer
Completed

Mon, 24 Sep 2007 12:00:00 EDT

Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects

Condition:   Cataract Extraction
Interventions:   Drug: Besifloxacin hydrochloride;   Drug: moxifloxacin hydrochloride;   Drug: gatifloxacin
Sponsor:   Bausch & Lomb Incorporated
Completed

Fri, 16 Jan 2009 12:00:00 EST

Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients

Condition:   Cataract
Intervention:   Drug: Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution
Sponsor:   Alcon Research
Completed

Wed, 22 May 2013 12:00:00 EDT

A Study to Investigate the Potential for AZD5672 to Affect the Electrical Conduction Pathways in the Heart

Condition:   Rheumatoid Arthritis
Interventions:   Drug: AZD5672;   Drug: Moxifloxacin;   Drug: placebo
Sponsors:   AstraZeneca;   Quintiles, Inc.
Completed

Fri, 24 Apr 2009 12:00:00 EDT

Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis

Condition:   Pulmonary Tuberculosis
Intervention:   Drug: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin
Sponsors:   Global Alliance for TB Drug Development;   European and Developing Countries Clinical Trials Partnership (EDCTP);   University College, London;   Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma;   Sanofi
Completed

Wed, 18 Mar 2009 12:00:00 EDT

A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections

Condition:   Intra-abdominal Infection
Interventions:   Drug: moxifloxacin;   Drug: ampicillin/sulbactam
Sponsor:   Kaohsiung Medical University Chung-Ho Memorial Hospital
Completed

Thu, 06 Aug 2009 12:00:00 EDT

Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis

Conditions:   Lung Diseases;   Bronchitis, Chronic
Interventions:   Drug: Avelox (Moxifloxacin, BAY12-8039);   Drug: Placebo
Sponsor:   Bayer
Completed

Tue, 15 May 2007 12:00:00 EDT

TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment

Condition:   Tuberculosis
Interventions:   Drug: Moxifloxacin;   Drug: Isoniazid
Sponsors:   Centers for Disease Control and Prevention;   US Department of Veterans Affairs;   Bayer;   National Institutes of Health (NIH)
Completed

Wed, 14 Sep 2005 12:00:00 EDT

Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery

Conditions:   Bacterial Infections;   Eye Infections;   Cataract Extraction
Interventions:   Drug: AzaSite Eye Drops;   Drug: Vigamox Eye Drops
Sponsor:   Merck Sharp & Dohme Corp.
Completed

Tue, 18 Dec 2007 12:00:00 EST

Oral Moxifloxacin Versus Cefazolin and Oral Probenecid in the Management of Skin and Soft Tissue Infections in the Emergency Department

Condition:   Cellulitis
Intervention:   Drug: Cefazolin and Moxifloxacin
Sponsor:   University of British Columbia
Unknown status

Tue, 09 May 2006 12:00:00 EDT

Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects

Condition:   Hepatitis C
Interventions:   Drug: BMS-791325;   Drug: Moxifloxacin;   Drug: Placebo matching BMS-791325
Sponsor:   Bristol-Myers Squibb
Completed

Wed, 12 Mar 2014 12:00:00 EDT

Determining the Effect of Antibiotic Drop Prophylaxis on the Conjunctival Flora

Condition:   Age-Related Macular Degeneration
Intervention:   Drug: Moxifloxacin 0.5%
Sponsors:   Lawson Health Research Institute;   St. Joseph's Healthcare Foundation
Completed

Fri, 13 Apr 2012 12:00:00 EDT

Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis

Condition:   Bacterial Conjunctivitis
Interventions:   Drug: Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%;   Other: Moxifloxacin AF Vehicle
Sponsor:   Alcon Research
Completed

Thu, 25 Sep 2008 12:00:00 EDT

Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses

Condition:   Abscess, Intra-Abdominal
Intervention:   Drug: Moxifloxacin/Metronidazole or Piperacillin/Tazobactam
Sponsors:   Hannover Medical School;   Bayer
Completed

Wed, 05 Mar 2008 12:00:00 EST

Moxifloxacin vs. Polytrim for Conjunctivitis

Condition:   Conjunctivitis
Interventions:   Drug: moxifloxacin;   Drug: polytrim
Sponsor:   University of Rochester
Completed

Thu, 27 Dec 2007 12:00:00 EST

Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects

Condition:   HIV/AIDS
Interventions:   Drug: Moxifloxacin;   Drug: Placebo;   Drug: Efavirenz
Sponsor:   Bristol-Myers Squibb
Completed

Tue, 17 Jun 2014 12:00:00 EDT

Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin

Condition:   HIV Infections
Interventions:   Drug: GSK3640254;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   ViiV Healthcare
Recruiting

Fri, 25 Sep 2020 12:00:00 EDT

Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers

Condition:   Infections, Respiratory Tract
Interventions:   Drug: GSK2140944;   Drug: GSK2140944 placebo;   Drug: Moxifloxacin;   Drug: Moxifloxacin placebo
Sponsor:   GlaxoSmithKline
Completed

Mon, 06 Oct 2014 12:00:00 EDT

To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)

Condition:   Contraception
Interventions:   Drug: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027);   Drug: Ortho Tri Cyclen Lo
Sponsor:   Bayer
Completed

Wed, 17 Sep 2008 12:00:00 EDT

Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults

Condition:   Healthy
Interventions:   Drug: Moxifloxacin (Avelox, BAY12-8039);   Drug: Moxifloxacin (BAY12-8039)
Sponsor:   Bayer
Completed

Tue, 23 Feb 2010 12:00:00 EST

Efficacy of Three Antibiotic Protocols for Aggressive Periodontitis Treatment

Condition:   Aggressive Periodontitis
Intervention:   Drug: Scaling and Root Planing combined with moxifloxacin
Sponsor:   Facultad Nacional de Salud Publica
Unknown status

Thu, 21 Jul 2016 12:00:00 EDT

Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Infection;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions:   Drug: moxifloxacin hydrochloride;   Drug: Placebo
Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
Terminated

Thu, 11 May 2006 12:00:00 EDT

Clinical Study to Evaluate Effect on QT/QTc Interval After Multiple Dose of Celecoxib

Condition:   Qt Interval, Variation in
Interventions:   Drug: Celecoxib;   Drug: Moxifloxacin;   Other: Water
Sponsor:   Samsung Medical Center
Completed

Wed, 30 Jan 2019 12:00:00 EST

A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery

Condition:   Cataracts
Interventions:   Drug: Moxifloxacin Ophthalmic;   Drug: Besifloxacin Ophthalmic
Sponsor:   Bucci Laser Vision Institute
Completed

Tue, 15 Feb 2011 12:00:00 EST

Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects

Condition:   Chronic Hepatitis C
Interventions:   Drug: BMS-790052;   Drug: Ortho Tri-Cyclen®
Sponsor:   Bristol-Myers Squibb
Completed

Thu, 24 Sep 2009 12:00:00 EDT

Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers

Condition:   QT/QTc Interval in Healthy Volunteers
Interventions:   Drug: WCK 5222;   Drug: IV placebo matched to WCK 5222 / Moxifloxacin IV solution;   Drug: Moxifloxacin 400-mg
Sponsor:   Wockhardt
Completed

Wed, 13 Jun 2018 12:00:00 EDT

BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia

Conditions:   Pneumonia, Aspiration;   Lung Abscess
Interventions:   Drug: Avelox (Moxifloxacin, BAY12-8039);   Drug: Sulbactam/Ampicillin
Sponsor:   Bayer
Completed

Mon, 11 Jan 2010 12:00:00 EST

A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs

Condition:   Infectious Diseases
Interventions:   Drug: Avelox (Moxifloxacin, BAY12-8039);   Drug: Amoxicilline/clavulanic
Sponsor:   Bayer
Completed

Mon, 26 Jan 2009 12:00:00 EST

Thorough QT/QTc Study of Multiple Oral Doses of NOMAC-E2 (Org 10486 0 + Org 2317) in Healthy Women (Study 292011)(P05802)

Condition:   Contraception
Interventions:   Drug: Moxifloxacin;   Drug: NOMAC-E2 (Org 10486-0 + Org 2317);   Drug: Moxifloxacin placebo;   Drug: NOMAC-E2 placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed

Fri, 24 Oct 2008 12:00:00 EDT

Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation

Condition:   Healthy
Interventions:   Drug: Gatifloxacin;   Drug: Moxifloxacin;   Drug: Besifloxacin
Sponsor:   Bausch & Lomb Incorporated
Completed

Thu, 21 May 2009 12:00:00 EDT

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers

Condition:   Healthy Volunteers
Interventions:   Drug: Buprenorphine transdermal patch;   Drug: Matching placebo transdermal patch;   Drug: Avelox (moxifloxacin hydrochloride) tablet
Sponsor:   Purdue Pharma LP
Completed

Tue, 22 Jun 2010 12:00:00 EDT

Uncomplicated Pelvic Inflammatory Disease. Treatment With Moxifloxacin.

Condition:   Pelvic Inflammatory Disease
Interventions:   Drug: Ofloxacin;   Drug: Avelox (Moxifloxacin, BAY12-8039)
Sponsor:   Bayer
Completed

Mon, 26 May 2008 12:00:00 EDT

Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Malate Sodium Chloride

Condition:   Pneumonia
Interventions:   Drug: Nemonoxacin 500 mg;   Drug: Nemonoxacin 650 mg;   Drug: Moxifloxacin 400 mg
Sponsors:   TaiGen Biotechnology Co., Ltd.;   QPS-Qualitix;   R&G Pharma Studies Co.,Ltd.
Completed

Wed, 18 Sep 2013 12:00:00 EDT

A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial

Condition:   Spasticity
Interventions:   Drug: Tizanidine;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Acorda Therapeutics
Completed

Wed, 24 Apr 2013 12:00:00 EDT

A Study to Assess the Cardiac Safety of Oritavancin in Healthy Volunteers

Condition:   Healthy
Interventions:   Drug: Single-Dose IV Oritavancin Diphosphate;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   The Medicines Company
Completed

Tue, 08 Jan 2013 12:00:00 EST

Effects of Three Single Oral Doses of Trazodone on the QTc Interval Duration in Healthy Volunteers

Condition:   Healthy
Interventions:   Drug: Trazodone 20 mg;   Drug: Trazodone 60 mg;   Drug: Trazodone 140 mg;   Drug: Placebo;   Drug: Moxifloxacin 400mg
Sponsors:   Aziende Chimiche Riunite Angelini Francesco S.p.A;   Cross Research S.A.;   eResearch Technology, Inc.
Completed

Fri, 04 May 2018 12:00:00 EDT

Electrophysiological Effects of Tipranavir Co-administered With Ritonavir on the QT Interval in Healthy Female and Male Subjects

Condition:   Healthy
Interventions:   Drug: TPV low;   Drug: Placebo;   Drug: Moxifloxacin;   Drug: TPV high;   Drug: RTV
Sponsor:   Boehringer Ingelheim
Completed

Thu, 25 Sep 2014 12:00:00 EDT

A Study of the Cardiac Effects of Danicopan in Healthy Adults

Condition:   Healthy
Interventions:   Drug: Danicopan;   Drug: Moxifloxacin-matching Placebo;   Drug: Danicopan-matching placebo;   Drug: Moxifloxacin
Sponsors:   Alexion Pharmaceuticals;   Achillion, a wholly owned subsidiary of Alexion
Completed

Mon, 23 Aug 2021 12:00:00 EDT

A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis

Condition:   Acute Bacterial Conjunctivitis
Interventions:   Drug: Besifloxacin;   Drug: Moxifloxacin solution
Sponsor:   Bausch & Lomb Incorporated
Completed

Tue, 04 Jul 2006 12:00:00 EDT

Efficacy and Safety of Sequential IV/PO Moxifloxacin in Comparison to IV Levofloxacin Plus IV Ceftriaxone Followed by PO Levofloxacin, in the Treatment of Patients With Community-acquired Pneumonia

Condition:   Pneumonia
Interventions:   Drug: Avelox (Moxifloxacin, BAY12-8039);   Drug: Levofloxacin + Ceftriaxone
Sponsor:   Bayer
Completed

Tue, 06 Feb 2007 12:00:00 EST

A Study to Test the Cardiac Effects of Padsevonil in Healthy Study Participants

Condition:   Healthy Study Participants
Interventions:   Drug: Padsevonil;   Drug: Moxifloxacin;   Drug: Placebo
Sponsor:   UCB Biopharma S.P.R.L.
Terminated

Tue, 15 Oct 2019 12:00:00 EDT

TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment

Condition:   Tuberculosis
Interventions:   Drug: Moxifloxacin (with rifampin, pyrazinamide, and ethambutol);   Drug: isoniazid
Sponsors:   Centers for Disease Control and Prevention;   Global Alliance for TB Drug Development;   Bayer
Completed

Mon, 05 Sep 2005 12:00:00 EDT

Using Device Delivering Ophthalmic Solution in a Spray Form Instead of Eye Drops

Condition:   Cataract
Intervention:   Device: Vigamox delivered via the device in spray form
Sponsor:   Advanced Ophthalmic Pharma
Withdrawn

Fri, 30 Nov 2007 12:00:00 EST

A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)

Condition:   TTR Cardiomyopathy
Interventions:   Drug: Period 1;   Drug: Period 2;   Drug: Period 3
Sponsor:   Pfizer
Completed

Fri, 25 Jan 2013 12:00:00 EST

This Study Will Investigate the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, With Moxifloxacin as a Positive Control in Healthy Volunteers.

Condition:   Obstetric Labour, Premature
Interventions:   Drug: Retosiban 100 mg;   Drug: Retosiban 800 mg;   Drug: Placebo;   Drug: Moxifloxacin 400 mg
Sponsor:   GlaxoSmithKline
Completed

Mon, 08 Oct 2012 12:00:00 EDT

Albiglutide Thorough ECG Study in Healthy Volunteers

Condition:   Diabetes Mellitus, Type 2
Interventions:   Biological: Albiglutide;   Drug: Moxifloxacin
Sponsor:   GlaxoSmithKline
Completed

Mon, 01 Aug 2011 12:00:00 EDT

A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm

Condition:   Healthy
Interventions:   Drug: Talampanel;   Drug: Moxifloxacin;   Drug: Placebo
Sponsors:   Teva Pharmaceutical Industries;   Cetero Research, San Antonio
Completed

Tue, 25 Aug 2009 12:00:00 EDT

Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration

Conditions:   Abscess;   Cysts
Intervention:   Drug: cefpirome and moxifloxacin administration
Sponsor:   Medical University of Vienna
Completed

Mon, 23 Jan 2006 12:00:00 EST

AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol

Condition:   Healthy
Interventions:   Drug: Ortho-Cyclen;   Drug: AG200-15
Sponsor:   Agile Therapeutics
Completed

Thu, 18 Nov 2010 12:00:00 EST

Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis

Conditions:   Blepharitis;   Conjunctivitis;   Keratitis
Interventions:   Drug: Moxifloxacin and Dexamethasone combined;   Drug: Moxifloxacin;   Drug: Dexamethasone
Sponsors:   Federal University of São Paulo;   Alcon Research
Completed

Tue, 12 Aug 2008 12:00:00 EDT

A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia

Condition:   Pneumonia
Interventions:   Drug: Avelox (Moxifloxacin, BAY12-8039);   Drug: Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin
Sponsor:   Bayer
Completed

Thu, 17 Jul 2008 12:00:00 EDT

EFFECTS OF MOXIFLOXACIN AND GEMIFLOXACIN ON BLOOD GLUCOSE LEVEL OF EUGLYCEMICS:A PRE-CLINICAL AND CLINICAL STUDY

Conditions:   Blood Glucose, Low;   Hypoglycemia
Interventions:   Drug: Moxifloxacin 400mg;   Drug: Gemifloxacin 320 MG
Sponsors:   Shaheed Benazir Bhutto University Sheringal Dir Upper;   Khyber Medical University Peshawar
Completed

Tue, 05 Jan 2021 12:00:00 EST

Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol

Condition:   Infection, Human Immunodeficiency Virus
Interventions:   Drug: Ortho-Cyclen;   Drug: Dolutegravir;   Drug: Placebo
Sponsors:   ViiV Healthcare;   Shionogi;   GlaxoSmithKline
Completed

Mon, 26 Dec 2011 12:00:00 EST

Vancomycin Plus Moxifloxacin Versus Vancomycin Plus Ceftazidime for the Treatment of Peritoneal Dialysis (PD)-Related Peritonitis

Condition:   Peritoneal Dialysis Associated Peritonitis
Interventions:   Drug: vancomycin;   Drug: moxifloxacin;   Drug: ceftazidime
Sponsor:   Peking University First Hospital
Completed

Wed, 01 Jun 2016 12:00:00 EDT

Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis

Condition:   Chronic Bronchitis
Interventions:   Drug: Avelox (Moxifloxacin, BAY12-8039);   Drug: Amoxicillin clavulanic acid
Sponsor:   Bayer
Completed

Fri, 11 Apr 2008 12:00:00 EDT

Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (Zibotentan) (10mg and 30mg) on QTc Interval

Condition:   Healthy
Interventions:   Drug: ZD4054;   Drug: Moxifloxacin;   Drug: ZD4054 Placebo;   Drug: Moxifloxacin placebo
Sponsor:   AstraZeneca
Completed

Fri, 11 Jul 2008 12:00:00 EDT

Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients

Condition:   Tuberculosis, Pulmonary
Interventions:   Drug: Isoniazid;   Drug: Rifampicin;   Drug: Pyrazinamide;   Drug: Ethambutol;   Drug: Moxifloxacin
Sponsors:   Tuberculosis Research Centre, India;   Indira Gandhi Govt. Medical College and Hospital (IGGMCH), Nagpur;   King George's Medical University, Lucknow;   Mahavir Hospital and Research Centre, Hyderabad;   Govt. Vellore Medical College and Hospital, Adukkamparai;   Lok Nayak hospital, New Delhi
Not yet recruiting

Thu, 16 Sep 2021 12:00:00 EDT

Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection

Condition:   Intraabdominal Infections
Interventions:   Drug: Moxifloxacin (Avelox, BAY12-8039);   Drug: Ertapenem;   Drug: Amoxicillin/Clavulanate;   Drug: Moxifloxacin placebo;   Drug: Ertapenem placebo;   Drug: Amoxicillin/Clavulanate placebo
Sponsor:   Bayer
Completed

Wed, 17 Feb 2010 12:00:00 EST

Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-hour Application

Condition:   Conjunctical Flora
Intervention:   Drug: gatifloxacin, moxifloxacin
Sponsor:   Stanford University
Withdrawn

Fri, 27 Apr 2007 12:00:00 EDT

A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Losmapimod;   Drug: Moxifloxacin;   Drug: Losmapimod matched Placebo;   Drug: Moxifloxacin Placebo
Sponsor:   GlaxoSmithKline
Completed

Thu, 27 Dec 2012 12:00:00 EST

A Study of the Effect of ASP1941 on Cardiac Repolarization in Healthy Subjects

Conditions:   Healthy Subjects;   Cardiac Repolarization
Interventions:   Drug: Placebo;   Drug: ASP1941;   Drug: Moxifloxacin
Sponsor:   Astellas Pharma Inc
Completed

Tue, 02 Nov 2010 12:00:00 EDT

Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)

Condition:   Bacterial Conjunctivitis
Interventions:   Drug: PRO-157;   Drug: Vigamox;   Drug: Zymar®;   Drug: Lagricel Ofteno®
Sponsor:   Laboratorios Sophia S.A de C.V.
Completed

Fri, 02 Dec 2016 12:00:00 EST

This Study in Healthy Men and Women Tests Whether BI 409306 Has an Effect on the ECG (Thorough QT Study)

Condition:   Healthy
Interventions:   Drug: BI 409306;   Drug: Moxifloxacin;   Drug: Placebo matching to BI 409306
Sponsor:   Boehringer Ingelheim
Completed

Wed, 01 May 2019 12:00:00 EDT

Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora

Condition:   Bacterial Conjunctivitis
Intervention:   Drug: VIGAMOX
Sponsors:   Alcon Research;   Tufts University
Completed

Mon, 10 Apr 2006 12:00:00 EDT


Guanfacine Immediate-release Electrocardiogram Results (QTc) Study

Condition:   Healthy Volunteers
Interventions:   Drug: immediate release guanfacine hydrochloride;   Drug: moxifloxacin;   Drug: Placebo
Sponsor:   Shire
Completed

Tue, 06 May 2008 12:00:00 EDT

Treatment of Patients With Acute Sinusitis

Condition:   Acute Bacterial Sinusitis
Intervention:   Drug: Avelox (Moxifloxacin, BAY12-8039)
Sponsor:   Bayer
Completed

Tue, 30 Jun 2009 12:00:00 EDT

Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects

Condition:   Alzheimer Disease
Interventions:   Drug: BMS-708163;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Bristol-Myers Squibb
Completed

Fri, 18 Sep 2009 12:00:00 EDT

Thorough Corrected QT Interval (QTc) Study To Evaluate Possible Effects of Prucalopride on ECG Parameters

Condition:   Constipation
Interventions:   Drug: prucalopride;   Drug: moxifloxacin;   Drug: placebo
Sponsor:   Movetis
Completed

Mon, 18 May 2009 12:00:00 EDT

Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male Subjects

Condition:   Healthy
Interventions:   Drug: BI 1356, low dose;   Drug: BI 1356, high dose;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Boehringer Ingelheim
Completed

Tue, 08 Jul 2014 12:00:00 EDT

A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects

Condition:   Healthy Volunteers
Interventions:   Drug: BGB-3111;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   BeiGene
Completed

Wed, 14 Feb 2018 12:00:00 EST

A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy Volunteers

Condition:   Restless Legs Syndrome
Interventions:   Drug: GEn 1200mg;   Drug: Gen 6000 mg;   Drug: GEn Placebo;   Drug: Moxifloxacin Placebo;   Drug: Moxifloxacin
Sponsor:   XenoPort, Inc.
Completed

Tue, 24 Jan 2012 12:00:00 EST

Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease

Condition:   Anti-Infective Agents
Intervention:   Drug: Avelox (Moxifloxacin, BAY12-8039)
Sponsor:   Bayer
Completed

Fri, 21 Sep 2012 12:00:00 EDT

A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxifloxacin in Healthy Adult Men and Women: A Thorough ECG Study

Condition:   Healthy
Interventions:   Drug: placebo;   Drug: lixivaptan;   Drug: moxifloxacin
Sponsors:   CardioKine Inc.;   Cardiokine Biopharma, LLC;   Biogen
Completed

Mon, 12 May 2008 12:00:00 EDT

Side Effect Profiles of Brand Name Versus Generic Oral Contraceptives

Condition:   Contraception
Interventions:   Drug: ortho tricyclen;   Drug: Trinessa
Sponsor:   William Beaumont Hospitals
Terminated

Mon, 20 Oct 2008 12:00:00 EDT

Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers

Conditions:   Bacterial Infections;   Eye Infections
Interventions:   Drug: AzaSite (azithromycin ophthalmic solution);   Drug: Vigamox (moxifloxacin hydrochloride ophthalmic solution)
Sponsor:   Merck Sharp & Dohme Corp.
Completed

Tue, 18 Dec 2007 12:00:00 EST

Study of Ocular Penetration of Topically Administered Fluoroquinolones

Condition:   Cataract Extraction
Interventions:   Drug: Moxifloxacin 0.5% ophthalmic solution;   Drug: Besifloxacin 0.6% ophthalmic suspension
Sponsor:   Johns Hopkins University
Completed

Fri, 19 Jun 2009 12:00:00 EDT

PK Analysis of Moxifloxacin in the Treatment of CAP

Condition:   Pneumonia
Intervention:  
Sponsor:   University of Aarhus
Completed

Thu, 14 Nov 2013 12:00:00 EST

A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers

Condition:   Healthy Male Volunteers
Interventions:   Drug: NXL104;   Drug: Ceftaroline;   Drug: Placebo Infusion;   Drug: Ceftazidime;   Drug: Moxifloxacin
Sponsor:   Pfizer
Completed

Mon, 07 Feb 2011 12:00:00 EST

Via Respimat® Inhaled BI 1744 CL Compared to Moxifloxacin and Placebo in Healthy Male and Female Volunteers

Condition:   Healthy
Interventions:   Drug: BI 1744 CL solution for inhalation;   Drug: Placebo matching BI 1744 CL;   Drug: Moxifloxacin (Avalox®)
Sponsor:   Boehringer Ingelheim
Completed

Tue, 24 Jun 2014 12:00:00 EDT

SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)

Condition:   Chronic Bronchitis
Intervention:   Drug: Moxifloxacin (Avelox, BAY12-8039)
Sponsor:   Bayer
Completed

Thu, 09 Apr 2009 12:00:00 EDT

Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

Condition:   Skin Diseases, Infectious
Interventions:   Drug: PTK 0796;   Drug: linezolid;   Drug: moxifloxacin
Sponsors:   Paratek Pharmaceuticals Inc;   Novartis Pharmaceuticals
Terminated

Thu, 19 Mar 2009 12:00:00 EDT

A Thorough QT Study of Telotristat Etiprate

Condition:   QT Interval
Interventions:   Drug: Telotristat etiprate;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Lexicon Pharmaceuticals
Completed

Wed, 04 Jun 2014 12:00:00 EDT

Study to Evaluate The Effect Of Sertraline on the Cardiac Repolarization in Healthy Subjects

Condition:   Healthy
Interventions:   Drug: Sertraline;   Drug: Moxifloxacin;   Drug: Drug - Placebo
Sponsor:   Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Completed

Mon, 11 Jan 2016 12:00:00 EST

A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms

Condition:   Anti-biotic Resistance
Interventions:   Drug: moxifloxacin 0.5% HCI ophthalmic solution;   Drug: gatifloxacin ophthalmic solution 0.3%
Sponsor:   Allergan
Completed

Fri, 03 Apr 2009 12:00:00 EDT

Electrocardiographic (ECG) Safety Study of Droxidopa at Clinical and Supratherapeutic Dose

Condition:   QTc Interval
Interventions:   Drug: Droxidopa;   Drug: Moxifloxacin;   Drug: Placebo
Sponsor:   Chelsea Therapeutics
Completed

Fri, 01 Apr 2011 12:00:00 EDT

Alternative Antibiotic Regime in the Treatment of GAgP

Conditions:   Generalized Aggressive Periodontitis;   Aggressive Periodontitis
Interventions:   Drug: Amoxicillin;   Drug: Metronidazole;   Drug: Moxifloxacin
Sponsor:   Kocaeli University
Completed

Fri, 22 Aug 2014 12:00:00 EDT

Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Participants

Condition:   Healthy
Interventions:   Drug: Tramadol HCl;   Drug: Moxifloxacin 400 mg;   Drug: Tramadol HCl Placebo;   Drug: Moxifloxacin Placebo
Sponsors:   Janssen Scientific Affairs, LLC;   Bausch Health Americas, Inc.;   Cipher Pharmaceuticals Inc.
Completed

Thu, 04 Dec 2014 12:00:00 EST

Antibiotic Resistance In Eye Surgeries

Conditions:   Antibiotic Resistance;   Ocular Surface Microbiome;   Gut Resistome
Intervention:   Drug: Moxifloxacin (Topical)
Sponsor:   University of California, San Francisco
Recruiting

Thu, 11 Feb 2021 12:00:00 EST

A Study to Assess the Effect of Single Doses of Daridorexant on Electrocardiogram Parameters in Healthy Subjects

Condition:   Healthy
Interventions:   Drug: Daridorexant;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Idorsia Pharmaceuticals Ltd.
Completed

Fri, 31 Jan 2020 12:00:00 EST

Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery

Condition:   Endophthalmitis
Interventions:   Drug: Moxifloxacin;   Drug: Placebo
Sponsor:   Jason Ahee, M.D.
Not yet recruiting

Wed, 09 Aug 2017 12:00:00 EDT

A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects

Conditions:   Diabetes;   Healthy
Interventions:   Drug: semaglutide;   Drug: placebo;   Drug: moxifloxacin
Sponsor:   Novo Nordisk A/S
Completed

Mon, 17 Feb 2014 12:00:00 EST

4-way Crossover QT Evaluation in Healthy Subjects

Condition:   Cardiac Repolarization in Healthy Subjects
Interventions:   Drug: ZTI-01;   Drug: Moxifloxacin 400mg;   Other: Placebo IV
Sponsor:   Nabriva Therapeutics AG
Completed

Wed, 17 Oct 2018 12:00:00 EDT

A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.

Condition:   Tuberculosis
Interventions:   Drug: PA-824;   Drug: bedaquiline;   Drug: moxifloxacin;   Drug: pyrazinamide;   Drug: isoniazid, rifampicin, pyrazinamide and ethambutol combination tablet
Sponsor:   Global Alliance for TB Drug Development
Completed

Fri, 18 Jul 2014 12:00:00 EDT

Complications After Lower Third Molar Surgery

Conditions:   Postoperative Complications;   Antibiotic Reaction;   Antibiotic Side Effect;   Antibiotic Resistant Infection;   Antibiotic Resistant Strain;   Infection, Bacterial;   Infection, Laboratory
Interventions:   Drug: Moxifloxacin 400 mg Oral Tablet;   Drug: Cefixime 400 mg Oral Tablet;   Other: Placebo
Sponsor:   University of Novi Sad
Active, not recruiting

Mon, 30 Aug 2021 12:00:00 EDT

Drug Interaction Oral Contraceptive Pill (OCP)

Condition:   Hepatitis C Virus
Interventions:   Drug: Ortho Tri-Cyclen®;   Drug: BMS-650032
Sponsor:   Bristol-Myers Squibb
Completed

Fri, 05 Feb 2010 12:00:00 EST

Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, to Healthy Male and Female Volunteers, With an Intra-individual Comparison to Moxifloxacin in a Subset of Volunteers

Condition:   Healthy
Interventions:   Drug: Cilobradine, low, film-coated tablets;   Drug: Cilobradine, high, film-coated tablets;   Drug: Placebo, film-coated tablets;   Drug: Moxifloxacin, film-coated tablets
Sponsor:   Boehringer Ingelheim
Completed

Wed, 15 Oct 2014 12:00:00 EDT

Reason Evaluation of Initial Treatment Failure in Patients With CAP

Condition:   Community-acquired Pneumonia
Intervention:   Drug: Moxifloxacin Hydrochloride and Sodium Chloride Injection
Sponsor:   Peking Union Medical College Hospital
Unknown status

Tue, 12 Sep 2017 12:00:00 EDT

AZD3293 Thorough QT Study in Healthy Male Volunteers

Condition:   Alzheimer's Disease
Interventions:   Drug: AZD3293;   Drug: Placebo;   Drug: Moxifloxacin
Sponsors:   AstraZeneca;   Parexel
Completed

Mon, 20 Jan 2014 12:00:00 EST

Evaluation of the Cardiac Effects of a Novel Food Ingredient in Healthy Male Subjects

Condition:   Cardiovascular Abnormalities
Interventions:   Other: R,R-monatin;   Other: Moxifloxacin;   Other: Placebo
Sponsors:   Cargill;   Ajinomoto Co., Inc.
Completed

Mon, 30 Nov 2015 12:00:00 EST

The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism

Conditions:   Long QT Syndrome;   Hypoglycemia
Interventions:   Drug: Moxifloxacin;   Drug: Placebo
Sponsor:   Signe Torekov
Enrolling by invitation

Mon, 11 Mar 2019 12:00:00 EDT

Pharmacokinetic Interaction Study in Indonesian Tuberculosis Patients Indonesia

Condition:   Tuberculosis
Intervention:   Drug: moxifloxacin
Sponsor:   Radboud University
Completed

Thu, 23 Mar 2006 12:00:00 EST

Comparison of Efficacy and Safety of Norgestimate-ethinyl Estradiol and Cyproterone Acetate-ethinyl Estradiol in the Treatment of Acne Vulgaris

Condition:   Acne Vulgaris
Intervention:   Drug: Norgestimate-ethinyl estradiol; Cyproterone acetate-ethinyl estradiol
Sponsor:   Johnson & Johnson Taiwan Ltd
Completed

Mon, 15 Sep 2008 12:00:00 EDT

TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

Condition:   Tuberculosis
Interventions:   Drug: rifapentine;   Drug: rifapentine and moxifloxacin;   Drug: control
Sponsors:   Centers for Disease Control and Prevention;   AIDS Clinical Trials Group
Completed

Wed, 08 Apr 2015 12:00:00 EDT

Effects of SQ109 on QTc Interval in Healthy Subjects

Condition:   Tuberculosis
Interventions:   Drug: SQ109;   Other: SQ109 Placebo;   Drug: Moxifloxacin
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Withdrawn

Tue, 11 Jun 2013 12:00:00 EDT

A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females

Condition:   Healthy Subjects
Interventions:   Drug: Placebo;   Drug: mirabegron;   Drug: moxifloxacin
Sponsor:   Astellas Pharma Inc
Completed

Mon, 13 Sep 2010 12:00:00 EDT

Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval

Conditions:   Duchenne and Becker Muscular Dystrophy;   Polycytemia Vera
Interventions:   Drug: ITF2357 10 mg/mL;   Drug: Placebo;   Drug: Moxifloxacin Hydrochloride
Sponsor:   Italfarmaco
Completed

Mon, 29 Mar 2021 12:00:00 EDT

Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)

Condition:   Pulmonary Tuberculosis
Interventions:   Drug: Moxifloxacin (M);   Drug: Pretomid (Pa);   Drug: Pyrazinamide (Z);   Drug: Rifafour
Sponsor:   Global Alliance for TB Drug Development
Completed

Fri, 23 Dec 2011 12:00:00 EST

ADASUVE 2-dose Thorough QT/QTc Study

Condition:   Healthy Volunteers
Interventions:   Drug: ADASUVE 10 mg 2 doses 2 hours apart;   Drug: Inhaled Placebo;   Drug: Oral moxifloxacin 400 mg;   Drug: Oral placebo
Sponsor:   Alexza Pharmaceuticals, Inc.
Completed

Wed, 15 May 2013 12:00:00 EDT

Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women

Conditions:   Insulin Sensitivity;   Cardiovascular Risk;   Perimenopausal Disorder
Intervention:   Drug: Ortho Cyclen®
Sponsors:   Virginia Commonwealth University;   American Heart Association
Completed

Mon, 21 Nov 2011 12:00:00 EST

A Study of Evacetrapib in Healthy Female Participants

Condition:   Healthy Volunteers
Interventions:   Drug: Ortho-Cyclen;   Drug: Evacetrapib
Sponsor:   Eli Lilly and Company
Completed

Tue, 11 Dec 2012 12:00:00 EST

A Study in Healthy Volunteers to Assess the Effect of Fedovapagon on the QT/QTC Interval

Condition:   Healthy
Interventions:   Drug: Fedovapagon;   Drug: Moxifloxacin;   Drug: Placebo (for fedovapagon)
Sponsor:   Vantia Ltd
Completed

Tue, 01 Sep 2015 12:00:00 EDT

Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials

Condition:   Pelvic Inflammatory Disease
Interventions:   Drug: Moxifloxacin;   Drug: Ofloxacin;   Drug: Metronidazole
Sponsor:   Istanbul Bakirkoy Maternity and Children Diseases Hospital
Completed

Tue, 26 Feb 2013 12:00:00 EST

Clinical Trial to Investigate the Effect on Corrected QT Interval Prolongation by Psychotropic Drugs

Condition:   Healthy
Interventions:   Drug: Escitalopram;   Drug: Quetiapine;   Drug: Moxifloxacin;   Other: Placebo
Sponsors:   Seoul National University Hospital;   Seoul National University Bundang Hospital
Completed

Fri, 07 Jun 2013 12:00:00 EDT

Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery

Condition:   Cataract
Intervention:   Drug: Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
Sponsor:   Alcon Research
Completed

Thu, 26 Mar 2009 12:00:00 EDT

Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections)

Condition:   Infection, Intra-abdominal
Interventions:   Drug: Avelox (Moxifloxacin, BAY12-8039);   Drug: Ceftriaxone + Metronidazole
Sponsor:   Bayer
Completed

Wed, 08 Oct 2008 12:00:00 EDT

The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers

Conditions:   Hypertension;   Mineralocorticoid Receptor Antagonist
Interventions:   Drug: CS-3150;   Drug: Moxifloxacin;   Drug: Placebo matching moxifloxacin tablet;   Drug: Placebo matching CS-3150
Sponsor:   Daiichi Sankyo, Inc.
Completed

Mon, 15 Jul 2019 12:00:00 EDT

A Thorough QT/QTc Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization

Condition:   Normal Healthy Subjects
Intervention:   Drug: Eravacyline and Moxifloxacin
Sponsor:   Tetraphase Pharmaceuticals, Inc.
Completed

Fri, 13 Sep 2013 12:00:00 EDT

A Study to Evaluate the Effect of GSK1322322 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers

Condition:   Infections, Bacterial
Interventions:   Drug: GSK1322322 1200 mg;   Drug: GSK1322322 3000 mg;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   GlaxoSmithKline
Withdrawn

Mon, 04 Mar 2013 12:00:00 EST

A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.

Condition:   Infections, Bacterial
Interventions:   Drug: GSK945237;   Drug: Placebo;   Drug: Linezolid;   Drug: Moxifloxacin
Sponsor:   GlaxoSmithKline
Withdrawn

Fri, 25 Dec 2009 12:00:00 EST

Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB

Condition:   Tuberculosis, Pulmonary
Intervention:   Drug: 4-month rifapentine-based regimen
Sponsors:   Kaohsiung Veterans General Hospital.;   National Taiwan University;   Taipei Veterans General Hospital, Taiwan;   Chang Gung Memorial Hospital;   Centers for Disease Control, Taiwan
Not yet recruiting

Fri, 23 Apr 2021 12:00:00 EDT

Study to Investigate the Effects of Single Intravenous Doses of Difelikefalin (CR845) on the QTc Interval in Healthy Subjects

Condition:   Healthy
Interventions:   Drug: CR845 0.5 mcg/kg IV;   Drug: CR845 3 mcg/kg IV;   Drug: Moxifloxacin 400 mg Oral Tablet;   Other: Placebo
Sponsor:   Cara Therapeutics, Inc.
Completed

Mon, 15 Jul 2019 12:00:00 EDT

A Study of Lasmiditan on the Heart in Healthy Participants

Condition:   Healthy
Interventions:   Drug: Lasmiditan;   Drug: Placebo;   Drug: Moxifloxacin
Sponsors:   Eli Lilly and Company;   CoLucid Pharmaceuticals
Completed

Wed, 14 Mar 2018 12:00:00 EDT

A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects

Condition:   Phenylketonuria
Interventions:   Drug: sapropterin dihydrochloride;   Drug: Moxifloxacin;   Drug: Moxifloxacin placebo
Sponsor:   BioMarin Pharmaceutical
Completed

Thu, 13 Nov 2008 12:00:00 EST

A Study to Evaluate the Effect of Two Different Repeat Doses of GSK2190915 on the QTc Interval.

Condition:   Asthma
Interventions:   Drug: GSK2190915 100mg;   Drug: GSK2190915 200mg;   Drug: moxifloxacin 400mg;   Drug: moxifloxacin placebo;   Drug: GSK2190915 placebo
Sponsor:   GlaxoSmithKline
Withdrawn

Sun, 04 Nov 2012 12:00:00 EDT

A Study to Evaluate the Effect of Repeat Oral Doses of YM443 on Cardiac Repolarization in Healthy Adults

Condition:   Functional Dyspepsia
Interventions:   Drug: YM443;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Astellas Pharma Inc
Completed

Wed, 25 Feb 2009 12:00:00 EST

Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers

Condition:   Pediculosis
Interventions:   Drug: Ha44;   Drug: Ha44 Placebo;   Drug: Moxifloxacin Placebo;   Drug: Moxifloxacin
Sponsor:   Dr. Reddy's Laboratories Limited
Completed

Thu, 26 Jan 2012 12:00:00 EST

Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women

Conditions:   Prolonged QTc Interval;   Pharmacokinetic
Interventions:   Drug: 100 mg CG5503 (tapentadol hydrochloride) PR tablet;   Drug: Placebo matching CG5503 PR tablet;   Drug: Placebo matching moxifloxacin capsule;   Drug: 400 mg Moxifloxacin tablet (overencapsulated)
Sponsor:   Grünenthal GmbH
Completed

Wed, 15 May 2019 12:00:00 EDT

A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects

Condition:   TQT Study
Interventions:   Drug: Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo;   Drug: Moxifloxacin 400mg;   Other: Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr);   Drug: Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)
Sponsors:   Spero Therapeutics;   Celerion
Completed

Thu, 23 Jan 2020 12:00:00 EST

Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat

Condition:   Coronary Artery Disease
Interventions:   Drug: Vericiguat (BAY1021189);   Drug: Moxifloxacin;   Drug: Placebo
Sponsors:   Bayer;   Merck Sharp & Dohme Corp.
Completed

Fri, 20 Apr 2018 12:00:00 EDT

Effect of Grapefruit on QT Interval in Healthy Volunteers and Patients With Congenital Long QT Syndrome

Condition:   Long QT Syndrome
Interventions:   Drug: Moxifloxacin;   Dietary Supplement: Grapefruit group
Sponsors:   Tel-Aviv Sourasky Medical Center;   Tel Aviv Medical Center
Completed

Thu, 11 Feb 2016 12:00:00 EST

Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants

Condition:   Heart Repolarization
Interventions:   Drug: Naltrexone HCl/bupropion HCl;   Other: Placebo;   Drug: Moxifloxacin
Sponsor:   Orexigen Therapeutics, Inc
Completed

Tue, 12 Apr 2016 12:00:00 EDT

A Phase I Study of the Effects of APF530 Exposure, Granisetron and Moxifloxacin

Condition:   Healthy
Intervention:   Drug: Withdraw treatment
Sponsor:   Heron Therapeutics
Completed

Mon, 15 Aug 2011 12:00:00 EDT

A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Ortho-Cyclen;   Biological: Dulaglutide
Sponsor:   Eli Lilly and Company
Completed

Mon, 24 Oct 2011 12:00:00 EDT

A Phase 1 QT Study in Healthy Male Subjects

Condition:   Clinical Pharmacology, Healthy Volunteer Study
Interventions:   Drug: Placebo;   Drug: Pomalidomide;   Drug: Moxifloxacin
Sponsor:   Celgene
Completed

Tue, 19 Nov 2013 12:00:00 EST

A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery

Condition:   Endophthalmitis Postoperative
Interventions:   Drug: Moxifloxacin hydrochloride 0.5% eye drops;   Drug: Dexamethasone 0.1% eye drops;   Drug: Intracameral Moxifloxacin 0.1%;   Drug: Subconjunctival Triamcinolone acetonide 4 mg /0.4 ml
Sponsors:   Suzan Rattan;   Al-Kindy College of Medicine
Completed

Fri, 17 Aug 2018 12:00:00 EDT

A Phase 1 Study To Evaluate The Effect Of Glasdegib On The Cardiac Repolarization In Healthy Subjects

Condition:   Healthy Volunteers
Interventions:   Drug: Glasdegib Therapeutic Exposure;   Drug: Glasdegib Supra-therapeutic Exposure;   Drug: Positive Control (Moxifloxacin);   Other: Placebo Control
Sponsor:   Pfizer
Completed

Mon, 22 May 2017 12:00:00 EDT

Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

Condition:   Tuberculosis
Interventions:   Drug: Rifapentine;   Drug: Moxifloxacin;   Drug: Rifampin;   Drug: Isoniazid;   Drug: Pyrazinamide;   Drug: Ethambutol;   Dietary Supplement: Pyridoxine
Sponsors:   Centers for Disease Control and Prevention;   AIDS Clinical Trials Group
Unknown status

Wed, 30 Sep 2015 12:00:00 EDT

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers

Condition:   ECG Effects
Interventions:   Drug: Buprenorphine transdermal patch;   Drug: Naltrexone tablet;   Drug: Placebos (for TDS and for naltrexone and for moxifloxacin);   Drug: Moxifloxacin tablet
Sponsor:   Purdue Pharma LP
Completed

Tue, 03 Dec 2013 12:00:00 EST

A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.

Condition:   Corneal Ulcers
Interventions:   Drug: Besivance 0.6% Ophthalmic Suspension;   Drug: Zymaxid 0.5% Ophthalmic Solution;   Drug: Vigamox 0.5% Ophthalmic Solution
Sponsors:   Cornea Consultants Of Nashville;   SCRI Development Innovations, LLC;   Bausch & Lomb Incorporated
Terminated

Tue, 27 Aug 2013 12:00:00 EDT

Adequate Duration of Antibiotic Treatment in Community-acquired Pneumonia With High Risk Class and Adequate Initial Clinical Response

Condition:   Community-acquired Pneumonia
Interventions:   Drug: Moxifloxacin;   Drug: Placebo
Sponsors:   David Garcia Cinca;   Fundacion Clinic per a la Recerca Biomédica;   Miquel Ferrer - Investigator Coordinator
Recruiting

Wed, 01 Aug 2018 12:00:00 EDT

A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects

Conditions:   Amount of NKTR-118 in Blood;   Variation in the Heart's Electrical Cycle
Interventions:   Drug: NKTR-118;   Drug: moxifloxacin;   Drug: Placebo
Sponsor:   AstraZeneca
Completed

Tue, 29 Mar 2011 12:00:00 EDT

Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects

Condition:   Prolonged QTc Interval
Interventions:   Drug: Deferiprone;   Drug: deferiprone matching placebo tablets;   Drug: moxifloxacin;   Drug: placebo
Sponsor:   ApoPharma
Completed

Thu, 23 May 2013 12:00:00 EDT

Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment

Condition:   Bacterial Conjunctivitis
Interventions:   Drug: Vigamox Ophthalmic Solution;   Drug: BSS placebo
Sponsors:   Alcon Research;   Topical Solutions Ltd.
Completed

Wed, 26 Nov 2008 12:00:00 EST

Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis

Condition:   Tuberculosis
Interventions:   Drug: Gatifloxacin;   Drug: Isoniazid;   Drug: Levofloxacin;   Drug: Linezolid;   Drug: Moxifloxacin
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Completed

Mon, 06 Nov 2006 12:00:00 EST

A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.

Condition:   Schizophrenia
Interventions:   Drug: SEP363856 150 mg;   Drug: Placebo;   Drug: moxifloxacin 400 mg
Sponsor:   Sunovion
Completed

Thu, 30 Apr 2020 12:00:00 EDT

Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy Volunteers

Condition:   Healthy Volunteers
Interventions:   Drug: Placebo;   Drug: GFT505;   Drug: Moxifloxacin 400 mg
Sponsors:   Genfit;   Eurofins Optimed;   CardiaBase;   PHINC DEVELOPMENT
Completed

Wed, 19 Mar 2014 12:00:00 EDT

Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)

Condition:   Breast Cancer
Interventions:   Drug: neratinib;   Other: Placebo;   Drug: Moxifloxacin
Sponsor:   Puma Biotechnology, Inc.
Completed

Wed, 02 Jul 2008 12:00:00 EDT

Thorough QT (TQT) Study of TD-4208 in Healthy Subjects

Condition:   Cardiac Repolarization in Healthy Subjects
Interventions:   Drug: TD-4208 175 mcg;   Drug: TD-4208 700 mcg;   Drug: Placebo for TD-4208;   Drug: Moxifloxacin 400 mg
Sponsors:   Mylan Inc.;   Theravance Biopharma
Completed

Thu, 30 Jun 2016 12:00:00 EDT

Oral Contraceptives in the Metabolic Syndrome

Conditions:   Metabolic Syndrome X;   Insulin Resistance;   Obesity;   Cardiovascular Diseases
Intervention:   Drug: Ortho Tri Cyclen
Sponsor:   Virginia Commonwealth University
Completed

Tue, 20 Sep 2005 12:00:00 EDT

Evaluation of Energy Drinks on Electrocardiographic, Vascular and Hematologic Parameters in Healthy Volunteers

Condition:   Cardiovascular Diseases
Interventions:   Other: energy drink;   Other: Moxifloxacin 400mg;   Other: Placebo
Sponsor:   David Grant U.S. Air Force Medical Center
Terminated

Mon, 16 Jan 2017 12:00:00 EST

A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects

Condition:   Healthy Subjects
Interventions:   Drug: Venlafaxine;   Drug: Moxifloxacin;   Drug: Drug - placebo
Sponsor:   Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Completed

Tue, 22 Dec 2015 12:00:00 EST

A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers

Condition:   Influenza, Human
Interventions:   Drug: 600 mg zanamivir + moxifloxacin placebo;   Drug: 1200 mg zanamivir + moxifloxacin placebo;   Drug: zanamivir placebo + moxifloxacin placebo;   Drug: zanamivir placebo + 400 mg moxifloxacin
Sponsor:   GlaxoSmithKline
Completed

Mon, 16 May 2011 12:00:00 EDT

A Trial To Evaluate Two Antibiotics For The Treatment Of Acute Exacerbation Of Chronic Bronchitis (AECB)

Condition:   Chronic Bronchitis
Interventions:   Other: Moxifloxacin Placebo;   Drug: Moxifloxacin;   Other: Azithromycin SR Placebo;   Drug: Azithromycin SR
Sponsor:   Pfizer
Completed

Wed, 16 Nov 2005 12:00:00 EST

QTc Study of Rosi XR in Healthy Volunteers

Condition:   Alzheimer's Disease
Interventions:   Drug: Rosi XR;   Other: Placebo;   Drug: Moxifloxacin
Sponsor:   GlaxoSmithKline
Withdrawn

Mon, 20 Apr 2009 12:00:00 EDT

Phase II Study of Oral Nafithromycin in CABP

Condition:   Community-Acquired Bacterial Pneumonia (CABP)
Interventions:   Drug: Nafithromycin 800 mg 3 days;   Drug: Nafithromycin 800 mg 5 days;   Drug: Moxifloxacin 400 mg
Sponsors:   Wockhardt;   ACM
Completed

Fri, 16 Sep 2016 12:00:00 EDT

To Study the Effect of Aprocitentan on the Electrical Activity of the Heart in Healthy Men and Women

Condition:   Healthy Subjects
Interventions:   Drug: Aprocitentan 25 mg;   Drug: Aprocitentan 100 mg;   Drug: Matching placebo;   Other: Moxifloxacin control to establish assay sensitivity
Sponsor:   Idorsia Pharmaceuticals Ltd.
Completed

Mon, 24 Feb 2020 12:00:00 EST

Safety and Efficacy Study of Different DAV132 Dose Regimens in Healthy Volunteers

Condition:   Healthy Subjects
Interventions:   Drug: Moxifloxacin;   Device: DAV132;   Other: Negative control
Sponsor:   Da Volterra
Completed

Wed, 28 Sep 2016 12:00:00 EDT

A Study of the Cardiac Effects of ALXN1840 in Healthy Adults

Condition:   Healthy
Interventions:   Drug: ALXN1840;   Drug: Placebo;   Drug: Moxifloxacin
Sponsors:   Alexion Pharmaceuticals;   PPD;   ERT: Clinical Trial Technology Solutions
Enrolling by invitation

Wed, 23 Sep 2020 12:00:00 EDT

A Study To Determine The Effect Of Single-dose PF-04965842 On QTc Interval In Healthy Volunteers Compared With Placebo and Moxifloxacin

Condition:   Healthy Volunteers
Interventions:   Drug: PF-04965842;   Drug: Moxifloxacin;   Drug: Placebo
Sponsor:   Pfizer
Completed

Fri, 29 Dec 2017 12:00:00 EST

Contraceptive Hormones and Women With Cystic Fibrosis

Condition:   Cystic Fibrosis Exacerbations While on and Off Hormonal Contraception
Interventions:   Other: Non-hormonal period;   Drug: Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg
Sponsors:   University of Pennsylvania;   Society of Family Planning
Terminated

Wed, 21 May 2014 12:00:00 EDT

A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes

Conditions:   Parkinson's Disease;   Off Episodes of Parkinson Disease
Interventions:   Drug: APL-130277;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Sunovion
Completed

Wed, 14 Jun 2017 12:00:00 EDT

A QT/QTc Evaluation Study of TS-142 in Healthy Adult Subjects

Condition:   Healthy Subjects
Interventions:   Drug: TS-142;   Drug: Moxifloxacin;   Drug: Placebo
Sponsor:   Taisho Pharmaceutical Co., Ltd.
Recruiting

Wed, 05 May 2021 12:00:00 EDT

A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant (DR-TB) Pulmonary TB Volunteers (PaSEM)

Conditions:   Tuberculosis, Pulmonary;   Tuberculosis, Multidrug-Resistant;   Tuberculosis, MDR;   Tuberculosis;   Drug-Resistant Tuberculosis
Interventions:   Drug: Pretomanid;   Drug: Bedaquiline;   Drug: moxifloxacin;   Drug: pyrazinamide
Sponsor:   Global Alliance for TB Drug Development
Not yet recruiting

Wed, 27 Nov 2019 12:00:00 EST

Study Evaluating The Effect of Bosutinib (SKI-606) On Cardiac Repolarization (Rhythms Of The Heart)

Condition:   Healthy Subjects
Interventions:   Drug: SKI-606;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Wyeth is now a wholly owned subsidiary of Pfizer
Completed

Thu, 04 Jun 2009 12:00:00 EDT

Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male and Female Volunteers

Condition:   Healthy
Interventions:   Drug: Treatment A;   Drug: Treatment B;   Drug: Treatment C;   Drug: Treatment D;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Boehringer Ingelheim
Completed

Mon, 06 Oct 2014 12:00:00 EDT

Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers

Condition:   Chronic Obstructive Pulmonary Disease
Interventions:   Drug: CHF 4226 pMDI;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Chiesi Farmaceutici S.p.A.
Completed

Wed, 22 Oct 2008 12:00:00 EDT

Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization

Condition:   Epilepsy
Interventions:   Drug: BIA 2-093;   Drug: Moxifloxacin;   Drug: Placebo
Sponsor:   Bial - Portela C S.A.
Completed

Wed, 05 Nov 2014 12:00:00 EST

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

Condition:   Infection, Human Immunodeficiency Virus
Interventions:   Drug: GSK1265744;   Drug: GSK1265744 matching placebo;   Drug: Moxifloxacin
Sponsors:   ViiV Healthcare;   GlaxoSmithKline
Completed

Mon, 06 Jan 2014 12:00:00 EST

Intracameral Antibiotic Safety Study

Conditions:   Intracameral Antibiotics;   Cataract Surgery;   Phacoemulsification;   Endophthalmitis;   Vancomycin;   Moxifloxacin
Interventions:   Drug: Vancomycin;   Drug: Moxifloxacin;   Drug: Placebo
Sponsor:   Panhandle Eye Group, LLP
Not yet recruiting

Thu, 29 Oct 2015 12:00:00 EDT

QTc Study GSK573719+GW642444

Condition:   Pulmonary Disease, Chronic Obstructive
Interventions:   Drug: Placebo Moxifloxacin;   Drug: Moxifloxacin;   Drug: GSK573719/Vilanterol 125/25mcg;   Drug: GSK573719;   Drug: GSK573719/Vilanterol 500/100mcg;   Drug: Placebo DPI
Sponsor:   GlaxoSmithKline
Completed

Mon, 30 Jan 2012 12:00:00 EST

A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis

Condition:   Bacterial Conjunctivitis
Interventions:   Drug: gatifloxacin;   Drug: moxifloxacin 0.5% eye drops
Sponsor:   Allergan
Completed

Mon, 23 Apr 2007 12:00:00 EDT

Phase I Study of OPC-61815

Condition:   Congestive Heart Failure
Interventions:   Drug: OPC-61815 16mg;   Drug: OPC-61815 32mg;   Drug: Moxifloxacin;   Drug: Placebos
Sponsor:   Otsuka Pharmaceutical Co., Ltd.
Completed

Fri, 27 Apr 2018 12:00:00 EDT

Shortening Treatment by Advancing Novel Drugs

Conditions:   Tuberculosis, Pulmonary, Drug Sensitive;   Tuberculosis, Pulmonary, Multi Drug-resistant
Interventions:   Drug: Moxifloxacin;   Drug: PA-824;   Drug: Pyrazinamide;   Drug: HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination);   Drug: HR (rifampicin plus isoniazid combination tablets)
Sponsor:   Global Alliance for TB Drug Development
Completed

Wed, 21 Jan 2015 12:00:00 EST

PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)

Conditions:   Infections and Infestations;   Pulmonary Tuberculosis
Interventions:   Drug: Delpazolid;   Drug: Bedaquiline, Delamanid, Moxifloxacin
Sponsors:   LegoChem Biosciences, Inc;   Ludwig-Maximilians - University of Munich;   Radboud University;   University of California, San Francisco
Not yet recruiting

Wed, 16 Sep 2020 12:00:00 EDT

Efficacy/Safety of Antibiotic Steroid Combination in Prevention of Post Operative Inflammation in LASIK Surgery

Condition:   Post Lasik Surgery Inflammation
Interventions:   Drug: antibiotic/steroid combination;   Drug: moxifloxacin/dexamethasone
Sponsor:   Federal University of São Paulo
Completed

Mon, 29 May 2006 12:00:00 EDT

A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects

Condition:   Healthy
Interventions:   Drug: PF-04447943;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Pfizer
Completed

Mon, 30 May 2016 12:00:00 EDT

Study to Evaluate the Effect Of WCK 2349 on the QT/QTc Interval in Health Volunteers

Condition:   Qt Interval, Variation in
Interventions:   Drug: WCK 2349;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Wockhardt
Completed

Fri, 15 Aug 2014 12:00:00 EDT

Efficacy/Safety of Antibiotic Steroid Combination in Prevention of Postoperative Inflammation in Cataract Surgery

Condition:   Inflammation Following Cataract Surgery
Interventions:   Drug: antibiotic/steroid combination;   Drug: moxifloxacin / dexamethasone
Sponsor:   Federal University of São Paulo
Completed

Mon, 29 May 2006 12:00:00 EDT

A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers

Condition:   Abnormalities, Cardiovascular
Interventions:   Drug: Volanesorsen;   Drug: Moxifloxacin;   Drug: Placebo
Sponsors:   Ionis Pharmaceuticals, Inc.;   Akcea Therapeutics
Completed

Thu, 22 Sep 2016 12:00:00 EDT

Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design

Condition:   Tuberculosis, Pulmonary
Interventions:   Drug: SQ109;   Drug: Rifampicin;   Drug: Moxifloxacin;   Drug: isoniazid;   Drug: pyrazinamide;   Drug: ethambutol;   Dietary Supplement: pyridoxine
Sponsors:   Michael Hoelscher;   Sequella, Inc.;   European and Developing Countries Clinical Trials Partnership (EDCTP);   German Federal Ministry of Education and Research;   Medical Research Council;   Radboud University
Completed

Thu, 07 Feb 2013 12:00:00 EST

Phase 3 Study - Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

Condition:   Skin Structures and Soft Tissue Infections
Interventions:   Drug: PTK 0796;   Drug: Linezolid
Sponsor:   Paratek Pharmaceuticals Inc
Withdrawn

Tue, 07 Apr 2009 12:00:00 EDT

A Thorough EKG Safety Study of TA-1790 (Avanafil)

Condition:   Erectile Dysfunction
Interventions:   Drug: moxifloxacin;   Drug: avanafil;   Drug: sugar pill
Sponsors:   VIVUS, Inc.;   Covance
Completed

Wed, 08 Oct 2008 12:00:00 EDT

Pharmacokinetic and Exploratory Electrocardiogram (ECG) Study

Condition:   Pharmacokinetics
Interventions:   Drug: Colchicine;   Drug: Moxifloxacin
Sponsor:   Mutual Pharmaceutical Company, Inc.
Completed

Mon, 23 Nov 2009 12:00:00 EST

A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers

Condition:   Healthy
Interventions:   Drug: Moxifloxacin;   Drug: ALKS 5461;   Drug: Placebo
Sponsor:   Alkermes, Inc.
Completed

Wed, 24 Jun 2015 12:00:00 EDT

Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy Tubes

Condition:   Acute Otitis Media
Interventions:   Drug: Moxidex otic solution;   Drug: Moxifloxacin otic solution;   Device: Tympanostomy tubes
Sponsor:   Alcon Research
Completed

Fri, 21 Dec 2007 12:00:00 EST

Optimizing the Antibiotic Treatment of Uncomplicated Acute Appendicitis

Condition:   Acute Appendicitis
Interventions:   Drug: Ertapenem;   Drug: Moxifloxacin
Sponsors:   Turku University Hospital;   Oulu University Hospital;   Tampere University Hospital;   Kuopio University Hospital;   Mikkeli Central Hospital;   Lapland Central Hospital;   Jyväskylä Central Hospital;   Satakunta Central Hospital;   Seinajoki Central Hospital
Active, not recruiting

Wed, 02 Aug 2017 12:00:00 EDT

Clinical Trial to Investigate the Pharmacokinetics of Second-Line Anti-Tuberculosis Agents

Condition:   Healthy
Interventions:   Drug: Levofloxacin and Streptomycin added;   Drug: Moxifloxacin and Kanamycin added
Sponsor:   Seoul National University Hospital
Completed

Thu, 01 May 2014 12:00:00 EDT

Study of the Electrocardiographic Effects of TA-8995

Condition:   Dyslipidaemia
Interventions:   Drug: TA-8995;   Drug: Moxifloxacin;   Drug: Placebo
Sponsor:   Xention Ltd
Completed

Tue, 16 Sep 2014 12:00:00 EDT

Effect of Estetrol Monohydrate (E4) on QTc Interval

Condition:   Prolonged QTc Interval
Interventions:   Drug: Estetrol 20 mg;   Drug: Estetrol 100 mg;   Drug: Placebo;   Drug: Moxifloxacin 400 mg
Sponsor:   Estetra
Recruiting

Mon, 29 Mar 2021 12:00:00 EDT

A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants

Condition:   Healthy
Interventions:   Drug: Seltorexant;   Other: Placebo Matched to Seltorexant;   Other: Placebo Matched to Moxifloxacin;   Drug: Moxifloxacin Dose 1
Sponsor:   Janssen Research & Development, LLC
Completed

Wed, 11 Apr 2018 12:00:00 EDT

PanACEA Sutezolid Dose-finding and Combination Evaluation

Conditions:   Pulmonary Tuberculosis;   Other Specified Pulmonary Tuberculosis
Interventions:   Drug: Sutezolid;   Drug: Bedaquiline, Delamanid, Moxifloxacin;   Drug: Midazolam oral solution
Sponsors:   Michael Hoelscher;   European and Developing Countries Clinical Trials Partnership (EDCTP);   Sequella, Inc.;   Radboud University;   University of California, San Francisco;   German Federal Ministry of Education and Research
Recruiting

Wed, 22 May 2019 12:00:00 EDT

Phase 1 Thorough QT (TQT) Study in Young Healthy Volunteers

Condition:   Fibromyalgia
Interventions:   Drug: esreboxetine;   Drug: placebo;   Drug: moxifloxacin
Sponsor:   Pfizer
Completed

Wed, 17 Dec 2008 12:00:00 EST

Corrected QT (QTc) Study With Flucticasone Furoate and GW642444

Condition:   Asthma
Interventions:   Drug: Fluticasone furoate (200 mcg)/GW642444 (25mcg) combination;   Drug: Fluticasone furoate (400 mcg)/GW642444 (50mcg) combination;   Drug: Placebo Inhaler;   Drug: Moxifloxacin 400mg;   Drug: Moxifloxacin placebo
Sponsor:   GlaxoSmithKline
Completed

Fri, 24 Sep 2010 12:00:00 EDT

To Investigate the Effects of AZD1981 on the QT Interval

Condition:   Asthma
Interventions:   Drug: AZD1981, 2000mg;   Drug: AZD1981, 200mg;   Drug: Moxifloxacin, 400mg;   Drug: Placebo
Sponsor:   AstraZeneca
Completed

Thu, 23 Dec 2010 12:00:00 EST

Investigate the Effect on the QT/QTc Interval of Repeated and Escalating Doses of AZD3480 During 6 Days

Condition:   Healthy
Interventions:   Drug: AZD3480;   Drug: Moxifloxacin;   Drug: PLACEBO
Sponsor:   AstraZeneca
Completed

Thu, 29 May 2008 12:00:00 EDT

Latency in Pulmonary Tuberculosis

Condition:   Pulmonary Tuberculosis
Intervention:   Drug: Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol
Sponsors:   Tuberculosis Research Centre, India;   National Institutes of Health (NIH)
Completed

Thu, 01 Jul 2010 12:00:00 EDT

A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects

Condition:   Healthy
Interventions:   Drug: mipomersen sodium;   Drug: moxifloxacin hydrochloride (Avelox®);   Drug: placebo
Sponsors:   Kastle Therapeutics, LLC;   Ionis Pharmaceuticals, Inc.
Completed

Mon, 22 Mar 2010 12:00:00 EDT

Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects

Condition:   Healthy
Interventions:   Drug: BI 10773 (low);   Drug: Moxifloxacin;   Drug: BI 10773 Placebo;   Drug: BI 10773 (high)
Sponsor:   Boehringer Ingelheim
Completed

Mon, 06 Sep 2010 12:00:00 EDT

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)

Condition:   Pulmonary Tuberculosis
Interventions:   Drug: PA-824;   Drug: Pyrazinamide;   Drug: TMC207;   Drug: Rifafour;   Drug: Moxifloxacin
Sponsor:   Global Alliance for TB Drug Development
Completed

Thu, 07 Oct 2010 12:00:00 EDT

VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers

Condition:   Hepatitis C
Intervention:   Drug: Telaprevir; Moxifloxacin; Placebo
Sponsors:   Tibotec BVBA;   Vertex Pharmaceuticals Incorporated
Completed

Wed, 09 Sep 2009 12:00:00 EDT

Assessment of the Effect of BI 201335 on the QT Interval in Healthy Female and Male Subjects

Condition:   Healthy
Interventions:   Drug: BI 201335 low dose;   Drug: BI 201335 placebo;   Drug: Moxifloxacin;   Drug: BI 201335 high dose
Sponsor:   Boehringer Ingelheim
Completed

Tue, 08 Jul 2014 12:00:00 EDT

A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects

Condition:   Autoimmune Diseases
Interventions:   Drug: CBP-307;   Drug: Placebo-matched CBP-307;   Drug: Moxifloxacin (Avelox);   Drug: Placebo-matched Moxifloxacin
Sponsor:   Suzhou Connect Biopharmaceuticals, Ltd.
Recruiting

Fri, 26 Mar 2021 12:00:00 EDT

Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer

Conditions:   Chronic Myeloproliferative Disorders;   Fever, Sweats, and Hot Flashes;   Infection;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Neutropenia;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: amoxicillin-clavulanate potassium;   Drug: ciprofloxacin;   Drug: moxifloxacin hydrochloride;   Procedure: management of therapy complications
Sponsor:   European Organisation for Research and Treatment of Cancer - EORTC
Terminated

Fri, 06 Jun 2003 12:00:00 EDT

A Study Measuring Effect of Pomaglumetad Methionil (LY2140023) on Electrocardiographs in Participants With Schizophrenia

Condition:   Schizophrenic Disorders
Interventions:   Drug: Pomaglumetad methionil;   Drug: Matching placebo;   Drug: Moxifloxacin
Sponsor:   Eli Lilly and Company
Completed

Fri, 25 May 2012 12:00:00 EDT

Thorough QT Study of Intravenous Amisulpride

Condition:   Healthy
Interventions:   Drug: APD421 5 mg;   Drug: APD421 40 mg;   Drug: Moxifloxacin;   Drug: Placebo
Sponsor:   Acacia Pharma Ltd
Completed

Fri, 22 Jan 2016 12:00:00 EST

The Optimization of Mycoplasm Pneumonia Antibiotic Therapy

Condition:   Mycoplasma Pneumonia
Interventions:   Drug: Moxifloxacin;   Drug: Cephalosporins and azithromycin
Sponsor:   Capital Medical University
Completed

Tue, 14 Dec 2010 12:00:00 EST

Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults

Conditions:   QT Intervals Changes;   QTc Intervals Changes
Interventions:   Drug: Omecamtiv Mecarbil (OM);   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Amgen
Completed

Mon, 25 Nov 2019 12:00:00 EST

A Study of LY3009104 in Healthy Participants

Condition:   Healthy Participants
Interventions:   Drug: LY3009104;   Drug: Placebo;   Drug: moxifloxacin
Sponsors:   Eli Lilly and Company;   Incyte Corporation
Completed

Wed, 22 Feb 2012 12:00:00 EST

Sativex Thorough QT/QTc Study

Condition:   Effects of Sativex on ECG
Interventions:   Drug: Placebo spray and oral moxifloxacin placebo;   Drug: Sativex spray and oral moxifloxacin placebo;   Drug: Placebo spray and moxifloxacin
Sponsor:   GW Pharmaceuticals Ltd.
Completed

Thu, 24 Mar 2011 12:00:00 EDT

CP-690,550 Thorough QTc Study

Condition:   Healthy
Interventions:   Drug: CP-690,550;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Pfizer
Completed

Thu, 06 Dec 2012 12:00:00 EST

A Thorough QTc Trial Evaluating the Effect of SNAC on Cardiac Repolarisation in Healthy Male Subjects.

Condition:   Healthy
Interventions:   Drug: SNAC;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Novo Nordisk A/S
Completed

Thu, 22 Sep 2016 12:00:00 EDT

Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects

Conditions:   Electrocardiogram Repolarisation Abnormality;   Gonococcal Infection
Interventions:   Drug: AZD0914;   Drug: Moxifloxacin;   Other: Placebo
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Completed

Fri, 03 Aug 2018 12:00:00 EDT

Cardiac Safety of Indacaterol

Conditions:   Healthy Volunteers;   Chronic Obstructive Pulmonary Disease
Interventions:   Drug: Indacaterol 150 µg;   Drug: Indacaterol 300 µg;   Drug: Indacaterol 600 µg;   Drug: Placebo;   Drug: Placebo/moxifloxacin
Sponsor:   Novartis Pharmaceuticals
Completed

Tue, 21 Dec 2010 12:00:00 EST

VEG111485: A QTc Study of Pazopanib

Condition:   Carcinoma, Renal Cell
Interventions:   Drug: Pazopanib;   Other: Placebo for pazopanib;   Drug: Moxifloxacin;   Other: Placebo for moxifloxacin
Sponsor:   GlaxoSmithKline
Completed

Fri, 13 Mar 2009 12:00:00 EDT

Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.

Condition:   Healthy
Interventions:   Drug: BI 207127;   Drug: BI 207127 placebo;   Drug: Faldaprevir placebo;   Drug: Faldaprevir;   Drug: Moxifloxacin (Avalox®)
Sponsor:   Boehringer Ingelheim
Completed

Fri, 18 Oct 2013 12:00:00 EDT

Study of Combined Oral Contraceptive Effects in Female Subjects

Condition:   Infection, Human Immunodeficiency Virus
Interventions:   Drug: BMS-955176;   Drug: Ortho Cyclen
Sponsors:   ViiV Healthcare;   GlaxoSmithKline
Completed

Fri, 06 Jun 2014 12:00:00 EDT

Assessment of Electrophysiological Effects of Dabigatran Etexilate as Single Dose on the QT Interval in Healthy Female and Male Subjects.

Condition:   Healthy
Interventions:   Drug: Dabigatran etexilate low;   Drug: Dabigatran etexilate high;   Drug: Moxifloxacin;   Drug: Placebo
Sponsor:   Boehringer Ingelheim
Completed

Mon, 23 Jun 2014 12:00:00 EDT

Multiple-Dose Study of Effect of Bardoxolone Methyl on QT/QTC Interval Volunteers

Condition:   Healthy Volunteers
Interventions:   Drug: Bardoxolone Methyl 20mg;   Drug: Bardoxolone Methyl 80mg;   Drug: Bardoxolone Methyl Placebo;   Drug: Moxifloxacin 400mg;   Drug: Moxifloxacin Placebo
Sponsor:   Reata Pharmaceuticals, Inc.
Completed

Fri, 21 Sep 2012 12:00:00 EDT

Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization

Condition:   Cardiac Conduction and Repolarization
Interventions:   Drug: Custirsen;   Drug: Placebo;   Drug: Moxifloxacin
Sponsors:   Achieve Life Sciences;   Teva Pharmaceutical Industries
Completed

Tue, 11 Jun 2013 12:00:00 EDT

A Study of the Cardiac Effects of ALXN2050 in Healthy Adults

Condition:   Healthy
Interventions:   Drug: ALXN2050;   Drug: ALXN2050-matching Placebo;   Drug: Moxifloxacin;   Drug: Moxifloxacin-matching Placebo
Sponsors:   Alexion Pharmaceuticals;   Celerion
Active, not recruiting

Wed, 09 Dec 2020 12:00:00 EST

Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy Subjects

Condition:   Healthy
Interventions:   Drug: CXA-101/tazobactam;   Drug: Moxifloxacin;   Drug: placebo
Sponsor:   Cubist Pharmaceuticals LLC
Completed

Mon, 27 Jul 2015 12:00:00 EDT

A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects

Condition:   Healthy Subjects
Interventions:   Drug: Exenatide;   Drug: Moxifloxacin;   Drug: Placebo comparator
Sponsors:   AstraZeneca;   Eli Lilly and Company
Completed

Wed, 16 Feb 2011 12:00:00 EST

Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery

Condition:   Cataracts
Interventions:   Drug: Bromfenac;   Drug: Moxifloxacin hydrochloride;   Drug: Prednisolone Acetate
Sponsor:   Bp Consulting, Inc
Completed

Thu, 25 Sep 2008 12:00:00 EDT

Influence of Pramipexole on the QT Interval of the ECG in Healthy Male and Female Volunteers

Condition:   Healthy
Interventions:   Drug: Pramipexole extended-release (ER) tablets;   Drug: Pramipexole immediate-release (IR) tablets;   Drug: Moxifloxacin;   Drug: Pramipexole Placebo;   Drug: Moxifloxacin Placebo
Sponsor:   Boehringer Ingelheim
Completed

Mon, 13 Oct 2014 12:00:00 EDT

Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women

Condition:   Parkinson Disease
Interventions:   Drug: BIA 9-1067;   Drug: Placebo;   Drug: moxifloxacin
Sponsor:   Bial - Portela C S.A.
Completed

Tue, 14 Feb 2012 12:00:00 EST

Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects

Condition:   Healthy Subjects
Interventions:   Drug: exenatide;   Drug: Moxifloxacin;   Drug: Placebo
Sponsors:   AstraZeneca;   Eli Lilly and Company
Completed

Tue, 06 May 2008 12:00:00 EDT

PRACTECAL-PKPD Sub Study

Conditions:   Multi-drug Resistant Tuberculosis;   Extensively Drug-Resistant Tuberculosis;   Pulmonary Tuberculosis
Interventions:   Drug: Bedaquiline;   Drug: Pretomanid;   Drug: Moxifloxacin;   Drug: Linezolid;   Drug: Clofazimine
Sponsors:   Medecins Sans Frontieres, Netherlands;   London School of Hygiene and Tropical Medicine;   Global Alliance for TB Drug Development;   University College, London;   Drugs for Neglected Diseases;   Swiss Tropical & Public Health Institute;   eResearch Technology, Inc.;   Ministry of Health, Republic of Uzbekistan;   World Health Organization;   Ministry of Public Health, Republic of Belarus;   THINK TB & HIV Investigative Network;   University of Liverpool;   Wits Health Consortium (Pty) Ltd;   Hackensack Meridian Health;   University of California, San Francisco;   Minsk Republican Research and Practical Centre for Pulmonology and Tuberculosis
Active, not recruiting

Mon, 09 Sep 2019 12:00:00 EDT

Acute Cholecystitis - Early Laparoscopic Surgery Versus Antibiotic Therapy and Delayed Elective Cholecystectomy

Condition:   Acute Cholecystitis
Interventions:   Drug: moxifloxacin;   Procedure: cholecystectomy
Sponsors:   Heidelberg University;   Bayer
Completed

Wed, 14 Mar 2007 12:00:00 EDT

A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval

Conditions:   Refractory Solid Tumors;   Lymphomas
Interventions:   Drug: Lenvatinib;   Drug: Moxifloxacin 400 mg;   Drug: Placebos (matched to 4 mg and 10 mg lenvatinib capsules).
Sponsor:   Eisai Inc.
Completed

Thu, 02 Feb 2012 12:00:00 EST

Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects

Condition:   Healthy
Interventions:   Drug: LX4211 800 mg;   Drug: LX4211 2000 mg;   Drug: moxifloxacin 400 mg;   Drug: LX4211 Placebo
Sponsor:   Lexicon Pharmaceuticals
Completed

Wed, 31 Jul 2013 12:00:00 EDT

A Phase II Study of an Otic Formulation in Treating Peri-Operative Tube Otorrhea

Condition:   Acute Otitis Media
Interventions:   Drug: Moxidex otic solution;   Drug: Moxifloxacin otic solution;   Device: Tympanostomy tubes
Sponsor:   Alcon Research
Completed

Fri, 21 Dec 2007 12:00:00 EST

A Study in Healthy Subjects to Investigate Whether Administration of Clazosentan Can Affect Normal Heart Function

Condition:   Healthy Subjects
Interventions:   Drug: Clazosentan;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Idorsia Pharmaceuticals Ltd.
Completed

Wed, 05 Sep 2018 12:00:00 EDT

T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers

Condition:   Healthy
Interventions:   Drug: Relacorilant;   Drug: Placebo to relacorilant;   Drug: Moxifloxacin
Sponsor:   Corcept Therapeutics
Completed

Fri, 12 Mar 2021 12:00:00 EST

Development of an Optimal Antibiotic Regime for Long-term Therapy in Stable Chronic Obstructive Pulmonary Disease (COPD)

Condition:   Chronic Obstructive Pulmonary Disease (COPD).
Interventions:   Drug: Moxifloxacin;   Drug: Azithromycin;   Drug: Doxycycline;   Drug: Placebo
Sponsors:   University College, London;   Royal Free Hampstead NHS Trust;   University of Cambridge;   National Institute for Health Research, United Kingdom
Unknown status

Wed, 20 Jul 2011 12:00:00 EDT

Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia

Condition:   Schizophrenia
Interventions:   Drug: Cariprazine;   Drug: Risperidone/Moxifloxacin
Sponsor:   Forest Laboratories
Completed

Mon, 20 Jun 2011 12:00:00 EDT

Risk of Acute Liver Injury in Users of Antimicrobials

Condition:   Drug-Induced Liver Injury
Interventions:   Drug: Moxifloxacin (Avelox, BAY12-8039);   Drug: Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
Sponsors:   Bayer;   RTI Health Solutions
Completed

Wed, 14 Sep 2011 12:00:00 EDT

A Double-blind, Randomised Study to Assess the Influence of Tiotropium (Spiriva®)

Condition:   Healthy
Interventions:   Drug: tiotropium 18 mcg or 54 mcg qd;   Drug: placebo matching tiotropium qd;   Drug: moxifloxacin 200 mg
Sponsor:   Boehringer Ingelheim
Completed

Wed, 23 Nov 2005 12:00:00 EST

Double-Blind Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Subjects

Condition:   Healthy
Interventions:   Drug: Setmelanotide;   Drug: Moxifloxacin;   Drug: Oral Placebo;   Drug: SC Placebo
Sponsor:   Rhythm Pharmaceuticals, Inc.
Recruiting

Thu, 16 Sep 2021 12:00:00 EDT

A Study to Investigate the Effect of PH-797804 on QTc Interval

Condition:   Healthy
Interventions:   Drug: PH-797804;   Drug: Moxifloxacin;   Drug: Placebo
Sponsor:   Pfizer
Completed

Mon, 27 May 2013 12:00:00 EDT

A Study to Evaluate the Effects of NST-4016 on QT/Corrected QT (QTc) Interval

Condition:   Dyslipidemias
Interventions:   Drug: NST-4016 600mg;   Drug: Placebo oral capsule;   Drug: Moxifloxacin 400mg;   Drug: NST-4016 2000mg
Sponsor:   NorthSea Therapeutics B.V.
Completed

Thu, 05 Jul 2018 12:00:00 EDT

Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)

Condition:   Healthy
Intervention:   Drug: granisetron
Sponsor:   Prostrakan Pharmaceuticals
Completed

Thu, 30 Apr 2009 12:00:00 EDT

A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: LY2409021;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Eli Lilly and Company
Completed

Wed, 26 Oct 2011 12:00:00 EDT

Effect of Liraglutide on Heart Frequency in Healthy Volunteers

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: placebo;   Drug: moxifloxacin;   Procedure: electrocardiogram (ECG)
Sponsor:   Novo Nordisk A/S
Completed

Tue, 24 Jan 2012 12:00:00 EST

Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Chinese Healthy Participants

Condition:   Healthy
Interventions:   Drug: Domperidone;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Janssen Research & Development, LLC
Completed

Wed, 29 Jun 2016 12:00:00 EDT

A Study to Investigate the Effects of PF00610335 on the QT/QTC Interval in Healthy Volunteers

Conditions:   Pulmonary Disease;   Lung Disease;   Moxifloxacin
Interventions:   Drug: PF-00610355;   Drug: moxifloxacin;   Drug: placebo
Sponsor:   Pfizer
Completed

Tue, 20 Apr 2010 12:00:00 EDT

Study to Assess the Effect of Macitentan on the Electrocardiogram (ECG) in Healthy Male and Female Subjects

Condition:   Healthy
Interventions:   Drug: Moxifloxacin 400 mg;   Drug: Macitentan 10 mg;   Drug: Macitentan 30 mg;   Other: Placebo
Sponsor:   Actelion
Completed

Fri, 31 Jan 2014 12:00:00 EST

A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants

Condition:   Healthy
Interventions:   Drug: Ibrutinib;   Drug: Moxifloxacin;   Drug: Ibrutinib-matching placebo;   Drug: Moxifloxacin-matching placebo
Sponsor:   Janssen Research & Development, LLC
Completed

Wed, 22 Oct 2014 12:00:00 EDT

Effect of BIA 5 1058 on Cardiac Repolarization

Conditions:   Cardiovascular Disease;   Pulmonary Arterial Hypertension;   Heart Failure
Interventions:   Drug: BIA 5-1058;   Drug: Placebo Oral Tablet;   Drug: Moxifloxacin 400 mg
Sponsors:   Bial - Portela C S.A.;   Covance
Completed

Thu, 05 Apr 2018 12:00:00 EDT

Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block

Conditions:   Drug-induced QT Prolongation;   Pharmacokinetics;   Pharmacodynamics
Interventions:   Drug: Dofetilide;   Drug: Mexiletine;   Drug: Lidocaine;   Drug: Moxifloxacin;   Drug: Diltiazem;   Drug: Placebo
Sponsors:   Food and Drug Administration (FDA);   Spaulding Clinical Research LLC
Completed

Thu, 04 Dec 2014 12:00:00 EST

Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants

Condition:   Healthy
Interventions:   Drug: ALS-008176;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Janssen Research & Development, LLC
Completed

Thu, 14 Jul 2016 12:00:00 EDT

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects

Conditions:   Systemic Lupus Erythematosus;   Healthy Participants
Interventions:   Drug: BMS-986165;   Drug: Moxifloxacin;   Other: Placebo
Sponsor:   Bristol-Myers Squibb
Completed

Wed, 30 May 2018 12:00:00 EDT

Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder

Conditions:   Schizophrenia;   Schizoaffective Disorder
Interventions:   Drug: OPC-34712 (4mg);   Drug: Moxifloxacin;   Drug: OPC-34712 (12mg);   Drug: Placebo
Sponsor:   Otsuka Pharmaceutical Development & Commercialization, Inc.
Completed

Fri, 26 Aug 2011 12:00:00 EDT

A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects

Condition:   Infection, Human Immunodeficiency Virus
Interventions:   Drug: BMS-955176, Placebo (Part 1);   Drug: BMS-955176, Moxifloxacin, Placebo (Part 2)
Sponsors:   ViiV Healthcare;   GlaxoSmithKline
Terminated

Thu, 15 Oct 2015 12:00:00 EDT

Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers

Condition:   Anaemia
Interventions:   Drug: GSK1278863 75 mg;   Drug: GSK1278863 500 mg;   Drug: Moxifloxacin 400 mg;   Drug: Placebo matching GSK1278863;   Drug: Placebo matching Moxifloxacin
Sponsor:   GlaxoSmithKline
Completed

Tue, 18 Nov 2014 12:00:00 EST

A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates

Condition:   Corneal Infiltrates
Interventions:   Drug: Moxifloxacin/dexamethasone phosphate ophthalmic solution;   Drug: Moxifloxacin ophthalmic solution 0.5%;   Drug: Dexamethasone phosphate solution, 0.1%
Sponsor:   Alcon Research
Terminated

Fri, 21 Dec 2007 12:00:00 EST

A Study to Evaluate the PF-06700841 Effect on QTc Interval in Healthy Volunteers

Condition:   Healthy
Interventions:   Drug: PF-06700841;   Drug: Placebo;   Drug: moxifloxacin
Sponsor:   Pfizer
Completed

Tue, 04 Sep 2018 12:00:00 EDT

Effect of Imeglimin on QT/QTc Intervals in Healthy Subjects

Condition:   Qt Interval, Variation in
Interventions:   Drug: Placebo;   Drug: Imeglimin;   Drug: Moxifloxacin
Sponsor:   Poxel SA
Completed

Wed, 05 Oct 2016 12:00:00 EDT

Acceptability of the NuvaRing Among Students

Condition:   Birth Control Compliance
Interventions:   Drug: Ortho Tri-cyclen Lo;   Device: NuvaRing
Sponsors:   University of Chicago;   Organon
Completed

Thu, 13 Mar 2008 12:00:00 EDT

A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects

Condition:   Pharmacokinetics
Interventions:   Drug: Lurasidone 40 mg;   Drug: Placebo 40 mg;   Drug: Ortho Tri-Cyclen
Sponsor:   Sunovion
Completed

Fri, 26 Oct 2007 12:00:00 EDT

A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery

Condition:   Patient Preference
Interventions:   Drug: Dexamethasone;   Other: Standard of care surgery
Sponsors:   Ophthalmic Consultants of Long Island;   Ocular Therapeutix, Inc.
Recruiting

Fri, 20 Dec 2019 12:00:00 EST

A Through QT/QTc Study of KW-6356

Condition:   Parkinson's Disease
Interventions:   Drug: KW-6356;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Kyowa Kirin Co., Ltd.
Completed

Mon, 13 Apr 2020 12:00:00 EDT

CAEB071 Thorough QTc Study in Healthy Volunteers

Condition:   Healthy
Interventions:   Drug: sotrastaurin;   Drug: placebo to sotrastaurin;   Drug: Avelox
Sponsor:   Novartis Pharmaceuticals
Completed

Wed, 09 May 2012 12:00:00 EDT

A Study With an Open-Label Active Control to Evaluate the Potential of Nestorone® to Delay Cardiac Repolarization in Healthy Female Volunteers

Condition:   Healthy
Interventions:   Drug: Supratherapuetic dose of Nestorone;   Drug: Placebo;   Drug: Moxifloxacin
Sponsors:   Population Council;   Parexel
Completed

Wed, 10 Sep 2014 12:00:00 EDT

Safety and Efficacy of Moxidex Otic

Condition:   Acute Otitis Media
Interventions:   Drug: Moxidex otic solution;   Drug: Moxifloxacin otic solution;   Other: Vehicle;   Device: Tympanostomy tubes
Sponsor:   Alcon Research
Terminated

Fri, 19 Feb 2010 12:00:00 EST

Study to Gather Information on the Influence of BAY1817080 on the Electrical Activity of the Heart Recorded by an Electrocardiogram in Healthy Male and Female Participants

Conditions:   Cough;   Endometriosis;   Overactive Bladder
Interventions:   Drug: BAY1817080;   Drug: Moxifloxacin;   Drug: Placebo
Sponsor:   Bayer
Completed

Tue, 09 Jun 2020 12:00:00 EDT

Clinical Pharmacology of FYU-981 (Effect on QT/QTc Interval)

Condition:   Healthy
Interventions:   Drug: FYU-981;   Drug: Placebo;   Drug: Moxifloxacin;   Drug: Moxifloxacin Placebo
Sponsor:   Fuji Yakuhin Co., Ltd.
Completed

Wed, 05 Aug 2015 12:00:00 EDT

A Study to Evaluate the Effect of IV ACHN-490 Injection on the QT/QTc Interval in Healthy Volunteers

Condition:   Cardiac Effects in Normal Healthy Volunteers
Interventions:   Drug: ACHN-490 Injection;   Drug: Moxifloxacin;   Drug: Placebo
Sponsors:   Achaogen, Inc.;   Department of Health and Human Services
Completed

Mon, 23 Jan 2012 12:00:00 EST

Thorough QT Assessment of Cedazuridine in Healthy Subjects

Condition:   Healthy Volunteers
Interventions:   Drug: Cedazuridine;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Astex Pharmaceuticals, Inc.
Recruiting

Thu, 08 Jul 2021 12:00:00 EDT

Safety Study on the Effect of Eurartesim™ on QT/QTc Interval Compared to Riamet in Healthy Volunteers

Condition:   Malaria, Falciparum
Interventions:   Drug: Eurartesim™;   Drug: Riamet®;   Other: Placebo and finally Moxifloxacin
Sponsors:   sigma-tau i.f.r. S.p.A.;   Medicines for Malaria Venture
Completed

Thu, 15 Apr 2010 12:00:00 EDT

A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)

Condition:   Healthy
Interventions:   Drug: Canagliflozin (JNJ-28431754);   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed

Fri, 08 Feb 2013 12:00:00 EST

A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects

Condition:   Healthy Subjects
Interventions:   Drug: Placebo;   Drug: E2609;   Drug: Moxifloxacin
Sponsor:   Eisai Inc.
Completed

Thu, 21 Aug 2014 12:00:00 EDT

A Phase 1, Randomized, Placebo-and Positive-Controlled Crossover Study to Determine the Effect of Single-Dose GC4419 on QTc Interval in Healthy Volunteers

Conditions:   Healthy Volunteers;   Healthy
Interventions:   Drug: GC4419 IV;   Drug: Placebo;   Drug: Oral moxifloxacin
Sponsors:   Galera Therapeutics, Inc.;   Syneos Health
Completed

Tue, 23 May 2017 12:00:00 EDT

Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects

Conditions:   Prolonged QTc Interval;   Pharmacokinetic
Interventions:   Drug: 100 μg cebranopadol;   Drug: 200 μg cebranopadol;   Drug: 400 μg cebranopadol;   Drug: Placebo to cebranopadol encapsulated tablets;   Drug: 400 mg Moxifloxacin;   Drug: Placebo to moxifloxacin encapsulated tablets
Sponsors:   Tris Pharma, Inc.;   Forest Laboratories
Completed

Tue, 21 May 2019 12:00:00 EDT

A Study of LY2484595 on the Electrical Activity of the Heart

Condition:   Healthy Volunteers
Interventions:   Drug: LY2484595;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Eli Lilly and Company
Completed

Thu, 23 Feb 2012 12:00:00 EST

TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-dose TMC207 on the QT/QTc Interval Under Fed Conditions

Condition:   Healthy Volunteer
Interventions:   Drug: Moxifloxacin;   Drug: TMC207;   Drug: TMC207 placebo;   Drug: Moxifloxacin placebo
Sponsor:   Tibotec BVBA
Completed

Tue, 08 Feb 2011 12:00:00 EST

Evaluation of the Effect of ATX-101 on QT/QTc Intervals

Condition:   Healthy
Interventions:   Drug: ATX-101 (10 mg/ml);   Drug: ATX-101 (20 mg/ml);   Drug: Moxifloxacin (400 mg);   Drug: Placebo vehicle (PBS)
Sponsor:   Kythera Biopharmaceuticals
Completed

Mon, 15 Oct 2012 12:00:00 EDT

Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects

Conditions:   Symptomatic Neurogenic Orthostatic Hypertension;   nOH
Interventions:   Drug: Ampreloxetine ;   Drug: Ampreloxetine ;   Drug: Ampreloxetine Placebo;   Drug: Moxifloxacin;   Drug: Moxifloxacin Placebo
Sponsor:   Theravance Biopharma
Completed

Wed, 30 Dec 2020 12:00:00 EST

A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants

Condition:   Healthy Volunteers
Interventions:   Drug: ACP-196;   Drug: Moxifloxacin 400 mg;   Drug: Placebo
Sponsor:   Acerta Pharma BV
Completed

Fri, 30 Apr 2021 12:00:00 EDT

A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects

Condition:   Healthy
Intervention:   Drug: Rivipansel
Sponsor:   GlycoMimetics Incorporated
Completed

Fri, 13 Sep 2013 12:00:00 EDT

A Study to Evaluate the Effects of Loperamide (JNJ-289679) on Electrocardiogram Intervals in Healthy Adult Participants

Condition:   Healthy Participants
Interventions:   Drug: Loperamide;   Other: Placebo;   Drug: Moxifloxacin
Sponsor:   Janssen Research & Development, LLC
Recruiting

Mon, 13 Jan 2020 12:00:00 EST

Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers

Condition:   Acinetobacter Baumannii-calcoaceticus Complex Infections
Interventions:   Drug: ETX2514;   Drug: Placebo;   Drug: moxifloxacin
Sponsor:   Entasis Therapeutics
Completed

Thu, 13 Jun 2019 12:00:00 EDT

TMC278-TiDP6-C152: A Study to Assess the Effects of TMC278 and Efavirenz (EFV) on the QT/QTc Interval (Heart Conduction and Heart Rhythm) in Healthy Volunteers.

Condition:   Human Volunteers
Intervention:   Drug: TMC278; Moxifloxacin; Efavirenz
Sponsor:   Tibotec Pharmaceuticals, Ireland
Completed

Mon, 01 Sep 2008 12:00:00 EDT

A Study of LY2216684 in Healthy Females

Condition:   Depressive Disorder, Major
Interventions:   Drug: LY2216684;   Drug: Ortho Cyclen;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Completed

Wed, 15 Jun 2011 12:00:00 EDT

Economic Evaluation of New MDR TB Regimens

Conditions:   Multi-drug Resistant Tuberculosis;   Extensively Drug-Resistant Tuberculosis;   Pulmonary Tuberculoses
Interventions:   Drug: Bedaquiline;   Drug: Pretomanid;   Drug: Moxifloxacin;   Drug: Linezolid;   Drug: Clofazimine;   Drug: Standard Drugs
Sponsors:   Medecins Sans Frontieres, Netherlands;   London School of Hygiene and Tropical Medicine;   Ministry of Health, Republic of Uzbekistan;   Ministry of Public Health, Republic of Belarus;   THINK TB & HIV Investigative Network;   University of Liverpool;   Wits Health Consortium (Pty) Ltd;   LSHTM Clinical Research Department
Recruiting

Fri, 20 Dec 2019 12:00:00 EST

A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants

Condition:   Healthy
Interventions:   Drug: JNJ-54861911-Therapeutic Dose;   Drug: JNJ-54861911 - Supratherapeutic Dose;   Drug: JNJ-54861911-Matched Placebo;   Drug: Moxifloxacin;   Drug: Moxifloxacin Matched Placebo
Sponsor:   Janssen Research & Development, LLC
Completed

Mon, 02 Jun 2014 12:00:00 EDT

A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers

Condition:   Healthy
Interventions:   Drug: Saroglitazar magnesium 4mg;   Drug: Placebos;   Drug: Moxifloxacin 400mg;   Drug: Saroglitazar magnesium 20 mg
Sponsor:   Zydus Therapeutics Inc.
Completed

Tue, 06 Aug 2019 12:00:00 EDT

Effect of Anagrelide Hydrochloride on Any Changes in Heart Function in Healthy Volunteers

Condition:   Healthy
Interventions:   Drug: Anagrelide 0.5 mg;   Drug: Anagrelide 2.5 mg;   Drug: Moxifloxacin;   Drug: Placebo
Sponsor:   Shire
Completed

Tue, 13 Mar 2012 12:00:00 EDT

Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects

Conditions:   Hyperuricemia;   Gout;   Qt Interval, Variation in
Interventions:   Drug: LC350189 200mg;   Drug: Placebo;   Drug: Moxifloxacin 400mg;   Drug: LC350189 600mg
Sponsor:   LG Chem
Not yet recruiting

Mon, 19 Jul 2021 12:00:00 EDT

Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy

Condition:   Helicobacter Infections
Interventions:   Drug: esomeprazole;   Drug: tripotassium dicitrate bismuthate;   Drug: metronidazole;   Drug: tetracycline;   Drug: moxifloxacin;   Drug: amoxicillin
Sponsor:   Seoul National University Bundang Hospital
Completed

Fri, 15 Feb 2013 12:00:00 EST

Dropless vs. Standard Drops Contralateral Eye Study

Condition:   Cataract
Interventions:   Drug: TriMoxiVanc;   Drug: Moxifloxacin HCl 0.5%;   Drug: Ilevro;   Drug: Prednisolone acetate 1%
Sponsors:   Carolina Eyecare Physicians, LLC;   Science in Vision
Completed

Tue, 04 Aug 2015 12:00:00 EDT

Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients

Conditions:   Tuberculosis, Pulmonary;   Tuberculosis, Multidrug-Resistant;   Tuberculosis, MDR;   Tuberculosis;   Drug-Resistant Tuberculosis
Interventions:   Drug: Pretomanid;   Drug: Bedaquiline;   Drug: Moxifloxacin;   Drug: Pyrazinamide;   Drug: HRZE;   Drug: HR
Sponsor:   Global Alliance for TB Drug Development
Active, not recruiting

Thu, 09 Nov 2017 12:00:00 EST

Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects

Condition:   Healthy
Interventions:   Drug: PF-00232798;   Drug: Placebo;   Drug: Moxifloxacin
Sponsors:   Pfizer;   ViiV Healthcare
Completed

Wed, 09 Jun 2010 12:00:00 EDT

A Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Healthy Volunteers

Condition:   Healthy
Interventions:   Drug: Treatment A (domperidone 10 mg);   Drug: Treatment B (domperidone 20 mg);   Drug: Treatment C (placebo);   Drug: Treatment D (moxifloxacin)
Sponsor:   Janssen Research & Development, LLC
Completed

Wed, 18 Jul 2012 12:00:00 EDT

Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers

Condition:   Healthy Volunteers
Interventions:   Drug: AKB-6548 (therapeutic dose);   Drug: AKB-6548 (supratherapeutic dose);   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Akebia Therapeutics
Completed

Thu, 13 Feb 2014 12:00:00 EST

Steroids and Cross-linking for Ulcer Treatment

Condition:   Keratitis Bacterial
Interventions:   Drug: Moxifloxacin Ophthalmic;   Drug: Difluprednate Ophthalmic;   Drug: Riboflavin Ophthalmic;   Other: Topical Placebo
Sponsors:   Thomas M. Lietman;   Kaiser Permanente;   Aravind Eye Care System;   National Eye Institute (NEI);   University of Miami
Recruiting

Fri, 20 Sep 2019 12:00:00 EDT

Evaluation of the Effect of Benzonatate on QT Intervals Following Single Dose Administration of Benzonatate to Healthy Volunteers

Condition:   Healthy Volunteers
Interventions:   Drug: Benzonatate 200 mg;   Drug: Benzonatate 800 mg;   Drug: Moxifloxacin 400 mg;   Drug: Placebo
Sponsor:   Pfizer
Completed

Mon, 04 Aug 2014 12:00:00 EDT

Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital

Conditions:   Delirium;   QT-prolongation
Intervention:   Drug: Haloperidol, azi/clari/erythromycin, levo/moxifloxacin, co-trimoxazole, vori/keto/flu/itraconazole, methadone, tacrolimus, sunitinib
Sponsors:   KU Leuven;   Agentschap voor Innovatie door Wetenschap en Technologie
Completed

Fri, 21 Feb 2014 12:00:00 EST

ANX-188 Thorough QT/QTc Study in Healthy Volunteers

Condition:   Healthy
Interventions:   Drug: ANX-188 Therapeutic Dose;   Drug: ANX-188 Supratherapeutic dose;   Drug: Saline;   Drug: Moxifloxacin
Sponsor:   Mast Therapeutics, Inc.
Completed

Wed, 13 Feb 2013 12:00:00 EST

Effects of Tucatinib on Cardiac Repolarization in Healthy Participants

Condition:   Healthy
Interventions:   Drug: tucatinib;   Drug: placebo;   Drug: moxifloxacin
Sponsor:   Seagen Inc.
Completed

Mon, 17 Dec 2018 12:00:00 EST

A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants

Condition:   Healthy
Interventions:   Drug: JNJ-63623872 2400 milligram (mg);   Drug: JNJ-63623872 3000 mg;   Drug: JNJ-63623872;   Drug: Moxifloxacin;   Drug: Placebo (Matching with JNJ-63623872 2400 mg);   Drug: Placebo (Matching with JNJ-63623872 3000 mg);   Drug: Placebo (Matching with JNJ-63623872 Dose);   Drug: Placebo (Matching with Moxifloxacin)
Sponsor:   Janssen Research & Development, LLC
Completed

Wed, 20 Jan 2016 12:00:00 EST

Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals

Condition:   Healthy
Interventions:   Drug: TRV130;   Drug: Moxifloxacin;   Drug: Placebo
Sponsor:   Trevena Inc.
Completed

Thu, 22 Jan 2015 12:00:00 EST

Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity

Condition:   Contraception
Interventions:   Drug: Ortho-Cyclen (R);   Drug: Ortho Evra (R);   Drug: extended use of Ortho Evra (R)
Sponsors:   University of Washington;   Ortho-McNeil Pharmaceutical
Unknown status

Mon, 26 Feb 2007 12:00:00 EST

Study of the Effect of Repeat Doses of Isavuconazole on Cardiac Repolarization

Conditions:   Pharmacokinetics of Isavuconazole;   Healthy Volunteers
Interventions:   Drug: Isavuconazole;   Drug: Placebo;   Drug: Moxifloxacin
Sponsors:   Astellas Pharma Global Development, Inc.;   Basilea Pharmaceutica International Ltd
Completed

Thu, 29 Mar 2012 12:00:00 EDT

A Study Evaluating the Effect of a Single-dose Oral Administration of Nemonoxacin Capsule on QTc Intervals and Heart Rhythms of Healthy Subjects and the Influence of Food Intake on QTc Intervals and Pharmacokinetic Characteristics

Condition:   Healthy Volunteers
Interventions:   Drug: Nemonoxacin 500Mg Capsule;   Drug: Moxifloxacin 400Mg Tablet;   Drug: Nemonoxacin 750Mg Capsule;   Drug: Placebo oral capsule
Sponsor:   TaiGen Biotechnology Co., Ltd.
Completed

Tue, 05 Dec 2017 12:00:00 EST

Study Investigating the Effect of Idalopirdine on Cardiac Repolarisation in Healthy Men

Condition:   Healthy Volunteers
Interventions:   Drug: Placebo;   Drug: ldalopirdine 120 mg;   Drug: Idalopirdine 360 mg;   Drug: Moxifloxacin 400 mg
Sponsor:   H. Lundbeck A/S
Completed

Wed, 06 May 2015 12:00:00 EDT

Cardiac Safety Evaluation of P03277

Condition:   Healthy Volunteers
Interventions:   Drug: P03277 0.1 mmol/kg;   Drug: Moxifloxacin 400mg;   Drug: NaCl 0.9%;   Drug: P03277 0.3 mmol/kg
Sponsor:   Guerbet
Completed

Wed, 05 Sep 2018 12:00:00 EDT

Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects

Conditions:   Cardiodynamics;   Safety;   Tolerability;   Pharmacokinetics
Interventions:   Drug: selexipag;   Drug: placebo for selexipag;   Drug: moxifloxacin;   Drug: moxifloxacin-matching placebo
Sponsor:   Actelion
Completed

Fri, 01 Aug 2014 12:00:00 EDT

Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)

Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Drug: Dexpramipexole;   Drug: Dexpramipexole Placebo;   Drug: Moxifloxacin
Sponsor:   Knopp Biosciences
Completed

Wed, 18 Jan 2012 12:00:00 EST

Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers

Condition:   Healthy
Interventions:   Drug: meropenem-vaborbactam;   Drug: Placebo;   Drug: Moxifloxacin
Sponsors:   Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.);   Biomedical Advanced Research and Development Authority
Completed

Wed, 20 Jun 2018 12:00:00 EDT

A Phase III Study of an Otic Formulation in Acute Otitis Externa

Condition:   Acute Otitis Externa
Interventions:   Drug: Moxidex otic solution;   Drug: Moxifloxacin otic solution;   Drug: Dexamethasone phosphate otic solution;   Device: Tympanostomy tubes
Sponsor:   Alcon Research
Completed

Wed, 10 Sep 2008 12:00:00 EDT

A Study to Investigate the Effect of GDC-0449 on the QT/QTc Interval in Healthy Female Subjects

Condition:   Healthy Volunteer
Interventions:   Drug: GDC-0449;   Drug: moxifloxacin;   Drug: placebo
Sponsor:   Genentech, Inc.
Completed

Mon, 02 Aug 2010 12:00:00 EDT

Staccato Loxapine Thorough QT/QTc Study

Condition:   Thorough QT/QTc Study
Interventions:   Drug: Inhaled loxapine;   Drug: Inhaled placebo;   Drug: Oral moxifloxacin;   Drug: Oral placebo
Sponsor:   Alexza Pharmaceuticals, Inc.
Completed

Thu, 02 Apr 2009 12:00:00 EDT

A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy Adults

Conditions:   Type 2 Diabetes Mellitus;   Diabetes Mellitus, Type 2
Intervention:   Drug: GSK189075
Sponsor:   GlaxoSmithKline
Completed

Thu, 20 Sep 2007 12:00:00 EDT

Steroids for Corneal Ulcers Trial

Conditions:   Corneal Ulcer;   Eye Infections, Bacterial
Interventions:   Drug: Antibiotics;   Drug: Topical corticosteroid;   Drug: Placebo
Sponsors:   Thomas M. Lietman;   Aravind Eye Hospitals, India;   Dartmouth-Hitchcock Medical Center;   National Eye Institute (NEI)
Completed

Wed, 10 May 2006 12:00:00 EDT

A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%

Condition:   Cataract
Interventions:   Drug: Dexycu intracameral dexamethasone;   Drug: Prednisolone Acetate
Sponsor:   Research Insight LLC
Completed

Tue, 18 Feb 2020 12:00:00 EST

Drug Interaction - Oral Contraceptive

Condition:   HIV Infections
Interventions:   Drug: Ortho Tri-Cyclen LO;   Drug: Ortho Cyclen;   Drug: Ortho Cyclen + Efavirenz
Sponsor:   Bristol-Myers Squibb
Completed

Wed, 15 Nov 2006 12:00:00 EST

Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

Conditions:   Cancer;   Solid Tumor
Interventions:   Biological: IMC-1121B;   Drug: Moxifloxacin;   Drug: Diphenhydramine
Sponsor:   Eli Lilly and Company
Completed

Mon, 23 Nov 2009 12:00:00 EST

VIGADEXA Gel Compared to VIGADEXA Solution Following Cataract Surgery

Condition:   Cataracts
Interventions:   Drug: Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel);   Drug: Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution)
Sponsor:   Alcon Research
Withdrawn

Tue, 24 Jan 2012 12:00:00 EST

A Study to Evaluate Folate Levels in Women Taking Oral Contraceptives

Conditions:   Neural Tube Defects;   Congenital, Hereditary, and Neonatal Diseases and Abnormalities;   Nervous System Malformations
Intervention:   Drug: Norgestimate-ethinyl estradiol, with or without folic acid
Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Withdrawn

Mon, 13 Mar 2006 12:00:00 EST

Phase 1 Thorough QT Study in Young Healthy Volunteers

Condition:   Postoperative Pain
Interventions:   Drug: SKY0402;   Drug: Moxifloxacin 400mg;   Drug: Placebo injection;   Drug: Placebo tablet
Sponsors:   Pacira Pharmaceuticals, Inc;   Richmond Pharmacology Limited
Completed

Wed, 13 Jun 2007 12:00:00 EDT

Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval

Condition:   Healthy Volunteer
Interventions:   Drug: ANG-3777 (Therapeutic Dose);   Drug: ANG-3777 (Supra-therapeutic Dose);   Drug: Placebo;   Drug: Moxifloxacin Hydrochloride
Sponsors:   Angion Biomedica Corp;   Quotient Sciences
Not yet recruiting

Mon, 24 May 2021 12:00:00 EDT

To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects

Condition:   Healthy Subjects
Interventions:   Drug: A: 400 mg pacritinib;   Other: B: Placebo;   Drug: C: 400 mg moxifloxacin
Sponsors:   CTI BioPharma;   Covance
Completed

Tue, 21 Jun 2016 12:00:00 EDT

To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men.

Condition:   Healthy Subjects
Interventions:   Drug: Combined oral contraceptives (COC);   Drug: Moxifloxacin 400mg;   Drug: Cenerimod 0.5 mg;   Drug: Cenerimod 4 mg;   Other: Charcoal, activated;   Drug: Matching Placebo
Sponsor:   Idorsia Pharmaceuticals Ltd.
Active, not recruiting

Wed, 05 Feb 2020 12:00:00 EST

Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females

Condition:   HIV Infections
Interventions:   Drug: Ortho Tri-Cyclen (ethinyl estradiol + norgestimate);   Drug: Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days
Sponsor:   Bristol-Myers Squibb
Completed

Thu, 27 Jul 2006 12:00:00 EDT

A Study To Assess The Effect Of Linezolid On QTc Interval

Condition:   Bacterial Infections
Interventions:   Drug: Placebo;   Drug: Linezolid 900 mg;   Drug: Linezolid 1200 mg;   Drug: Linezolid 600 mg;   Drug: Moxifloxacin 400 mg
Sponsor:   Pfizer
Completed

Fri, 21 Nov 2008 12:00:00 EST

Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)

Conditions:   Tuberculosis, Multidrug-Resistant;   Extensively Drug-Resistant Tuberculosis;   Tuberculosis, Pulmonary
Interventions:   Drug: Bedaquiline;   Drug: Pretomanid;   Drug: Moxifloxacin;   Drug: Linezolid;   Drug: Clofazimine;   Drug: Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
Sponsors:   Medecins Sans Frontieres, Netherlands;   London School of Hygiene and Tropical Medicine;   Global Alliance for TB Drug Development;   University College, London;   Drugs for Neglected Diseases;   Swiss Tropical & Public Health Institute;   eResearch Technology, Inc.;   Ministry of Health, Republic of Uzbekistan;   World Health Organization;   Ministry of Public Health, Republic of Belarus;   THINK TB & HIV Investigative Network;   University of Liverpool;   Wits Health Consortium (Pty) Ltd;   Rutgers, The State University of New Jersey;   University of California, San Francisco
Active, not recruiting

Wed, 28 Oct 2015 12:00:00 EDT

Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas

Conditions:   Keratoconus;   Ectasia;   Degeneration
Interventions:   Drug: Ciprofloxicin or Vigamox or other.;   Drug: Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc);   Drug: Steroid (FML, Pred Forte, Flarex, etc.)
Sponsor:   Cxlusa
Terminated

Fri, 27 Aug 2010 12:00:00 EDT

The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial

Condition:   Appendicitis
Interventions:   Drug: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin;   Procedure: Appendectomy
Sponsors:   University of Washington;   Patient-Centered Outcomes Research Institute
Completed

Wed, 15 Jun 2016 12:00:00 EDT

Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas

Conditions:   Keratoconus;   Ectasia;   Degeneration
Interventions:   Drug: Ciprofloxicine or Vigamox or other.;   Drug: Nonsteroidal (Acular, Voltaren Xibrom, etc);   Drug: Steroid (FML, Pred Forte, Flarex, etc.)
Sponsor:   Cxlusa
Terminated

Wed, 02 Dec 2009 12:00:00 EST

Study of the Effects of Intravenous Exenatide on Cardiac Repolarization

Condition:   Healthy Adult Male and Female Volunteers
Interventions:   Drug: Exenatide;   Drug: Placebo;   Drug: Moxifloxacin;   Drug: Palonosetron
Sponsor:   Intarcia Therapeutics
Completed

Fri, 08 Jan 2016 12:00:00 EST

A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women

Condition:   Anemia
Interventions:   Drug: ferumoxytol;   Drug: moxifloxacin;   Drug: placebo
Sponsor:   AMAG Pharmaceuticals, Inc.
Completed

Fri, 04 Aug 2006 12:00:00 EDT

Evaluation of Dose-Dependent Repeated-Dose Neramexane Effects on Cardiac Repolarisation (QT/QTc Interval Duration): Electrocardiogram (ECG) Study in Healthy Adult Subjects

Condition:   Healthy Subjects
Intervention:   Drug: Neramexane
Sponsor:   Merz Pharmaceuticals GmbH
Completed

Thu, 17 Sep 2009 12:00:00 EDT

A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects

Condition:   Healthy Volunteer
Interventions:   Drug: TR-701 FA 1200 mg;   Drug: Moxifloxacin 400 mg;   Drug: TR-701 FA 200 mg plus Placebo;   Drug: Placebo
Sponsor:   Trius Therapeutics LLC
Completed

Fri, 28 Oct 2011 12:00:00 EDT

Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose

Condition:   Healthy Subjects
Interventions:   Drug: Moxifloxacin;   Drug: Placebo;   Drug: Lanifibranor
Sponsors:   Inventiva Pharma;   Parexel
Completed

Thu, 07 Mar 2019 12:00:00 EST

A Bioequivalence Study of Norgestimate /Ethinyl Estradiol (NGM/EE) Tablets Manufactured at 2 Different Facilities

Condition:   Healthy
Interventions:   Drug: Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Wet Process);   Drug: Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Dry Process)
Sponsor:   Janssen Research & Development, LLC
Completed

Wed, 30 Apr 2014 12:00:00 EDT

Anti-inflammatory Action of Oral Clarithromycin in Community-acquired Pneumonia

Conditions:   Community-acquired Pneumonia;   Sepsis;   Inflammatory Response;   Mortality;   Biomarkers;   SIRS
Interventions:   Drug: Tablets;   Drug: Clarithromycin 500mg
Sponsor:   Hellenic Institute for the Study of Sepsis
Recruiting

Tue, 26 Jan 2021 12:00:00 EST

A Thorough Corrected QT Interval Trial

Condition:   Dyslipidemia
Interventions:   Drug: K-877 Low Dose;   Drug: Moxifloxacin;   Other: Placebo;   Drug: K-877 High Dose
Sponsor:   Kowa Research Institute, Inc.
Completed

Thu, 27 Feb 2014 12:00:00 EST

A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval

Condition:   Healthy Volunteer
Interventions:   Other: Placebo RO4602522;   Drug: RO4602522;   Drug: moxifloxacin;   Other: moxifloxacin placebo
Sponsor:   Hoffmann-La Roche
Completed

Fri, 04 Apr 2014 12:00:00 EDT

A Study to Evaluate Effects of CC-99677 on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Participants

Condition:   Healthy Volunteers
Interventions:   Drug: Oral Contraceptive (Ortho Tri-Cyclen or its generic equivalent);   Drug: CC-99677
Sponsor:   Celgene
Recruiting

Fri, 22 Jan 2021 12:00:00 EST

A Study to Determine if Technosphere® Inhalation Powder (FDKP) Causes ECG Changes (QTc) Following the Medication's Inhaled Administration.

Condition:   Healthy Subjects
Interventions:   Drug: Technosphere Inhalation Powder (FDKP);   Drug: Moxifloxacin;   Drug: Placebo
Sponsor:   Mannkind Corporation
Completed

Thu, 24 Jul 2008 12:00:00 EDT

Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects

Condition:   Healthy
Interventions:   Drug: tigecycline;   Drug: moxifloxacin;   Drug: 100 mL 0.9% Sodium Chloride intravenous;   Drug: placebo
Sponsor:   Pfizer
Completed

Tue, 01 Feb 2011 12:00:00 EST

Acute Appendicitis and Microbiota - Etiology of Appendicitis and Antibiotic Therapy Effects

Condition:   Acute Appendicitis
Interventions:   Drug: Ertapenem followed by levofloxacin and metronidazole;   Drug: Moxifloxacin;   Procedure: Appendectomy;   Other: Placebo
Sponsors:   Turku University Hospital;   Tampere University Hospital;   Oulu University Hospital;   Kuopio University Hospital;   Helsinki University Central Hospital;   Jyväskylä Central Hospital
Enrolling by invitation

Tue, 22 Aug 2017 12:00:00 EDT

Staccato Prochlorperazine Thorough QT/QTc

Condition:   Cardiotoxicity
Interventions:   Drug: Inhaled placebo;   Drug: Oral placebo;   Drug: Inhaled prochlorperazine 5 mg;   Drug: Inhaled prochlorperazine 10 mg;   Drug: Oral moxifloxacin
Sponsor:   Alexza Pharmaceuticals, Inc.
Completed

Fri, 12 Oct 2007 12:00:00 EDT

A Pharmacokinetic And QT Study Of CP-751,871 In Healthy Subjects

Condition:   Healthy Volunteers
Interventions:   Biological: CP-751,871;   Biological: CP-751,871, moxifloxacin, saline
Sponsor:   Pfizer
Terminated

Tue, 23 Jun 2009 12:00:00 EDT

Determine the Effects of C-administration of AZD7325 and an Oral Contraceptive in Healthy Female Subjects

Condition:   Pharmacokinetics
Interventions:   Drug: monophasic oral contraceptive;   Drug: AZD7325
Sponsor:   AstraZeneca
Suspended

Wed, 13 May 2009 12:00:00 EDT

A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine

Condition:   Healthy
Interventions:   Drug: bilastine;   Drug: Bilastine;   Drug: Bilastine & Ketoconazole;   Drug: Moxifloxacin;   Drug: Placebo
Sponsor:   Faes Farma, S.A.
Completed

Tue, 09 Jan 2007 12:00:00 EST

AMS VS MOXI Ketek vs Avelox in AMS

Condition:   Maxillary Sinusitis
Intervention:   Drug: Telithromycin
Sponsor:   Sanofi
Completed

Mon, 01 Oct 2007 12:00:00 EDT

Efficacy and Safety of Saturno IIB Association on the Control of Ocular Inflammation Post-phacoemulsification

Conditions:   Ocular Inflammation;   Cataract
Interventions:   Drug: SATURNO II association;   Drug: Vigadexa®
Sponsor:   EMS
Recruiting

Mon, 09 Jul 2018 12:00:00 EDT

Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female Subjects

Condition:   Healthy
Interventions:   Drug: Ponesimod Placebo;   Drug: Moxifloxacin Placebo;   Drug: Ponesimod 10 mg;   Drug: Ponesimod 20 mg;   Drug: Ponesimod 40 mg;   Drug: Ponesimod 60 mg;   Drug: Ponesimod 80 mg;   Drug: Ponesimod 100 mg;   Drug: Moxifloxacin 400 mg
Sponsor:   Actelion
Completed

Tue, 13 May 2014 12:00:00 EDT

Tafenoquine Thorough QTc Study in Healthy Subjects

Condition:   Malaria, Vivax
Interventions:   Drug: Tafenoquine 300mg;   Drug: Tafenoquine 600mg;   Drug: Tafenoquine 1200mg;   Drug: moxifloxacin;   Drug: Placebo for Tafenoquine;   Drug: Placebo for moxifloxaxin
Sponsor:   GlaxoSmithKline
Completed

Tue, 27 Aug 2013 12:00:00 EDT

Research on New Regimens for Retreatment Pulmonary Tuberculosis

Condition:   Reinfection Pulmonary Tuberculosis
Interventions:   Drug: Isoniazid Aminosalicylate Tablets;   Drug: Streptomycin injectable
Sponsors:   Shanghai Pulmonary Hospital, Shanghai, China;   Shanghai Center for Disease Control and Prevention;   Jiangsu Province Centers for Disease Control and Prevention;   Zhejiang University;   Centers for Disease Control and Prevention
Unknown status

Tue, 06 Jan 2015 12:00:00 EST

Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart

Condition:   Atherosclerosis
Intervention:   Drug: Darapladib
Sponsor:   GlaxoSmithKline
Completed

Wed, 13 Dec 2006 12:00:00 EST

Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial

Condition:   Multidrug Resistant Tuberculosis
Interventions:   Drug: Bedaquiline;   Drug: Pretomanid;   Drug: Moxifloxacin;   Drug: Linezolid;   Drug: Clofazimine;   Drug: Directly observed therapy (DOT)
Sponsors:   Medecins Sans Frontieres, Netherlands;   University of Sussex;   London School of Hygiene and Tropical Medicine;   THINK TB & HIV Investigative Network;   Wits Health Consortium (Pty) Ltd;   Ministry of Public Health, Republic of Belarus;   Ministry of Health, Republic of Uzbekistan
Recruiting

Wed, 08 May 2019 12:00:00 EDT

A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers

Condition:   Healthy Volunteer
Interventions:   Drug: Moxifloxacin;   Drug: RO4917838;   Drug: RO4917838 placebo
Sponsor:   Hoffmann-La Roche
Completed

Wed, 06 Jun 2012 12:00:00 EDT

Bacteriology and Inflammation in Bronchiectasis

Condition:   Bronchiectasis
Interventions:   Drug: Fluroquinolones;   Drug: Beta-lactamase inhibitor
Sponsor:   Guangzhou Institute of Respiratory Disease
Recruiting

Fri, 04 Jan 2013 12:00:00 EST

Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100

Condition:   Drug Toxicity
Interventions:   Drug: HPN-100;   Drug: HPN-100 or Placebo;   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Horizon Pharma Ireland, Ltd., Dublin Ireland
Completed

Thu, 03 Jun 2010 12:00:00 EDT

Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator

Condition:   Cataract
Interventions:   Drug: 1.5% levofloxacin ophthalmic solution;   Drug: 0.5% moxifloxacin hydrochloride ophthalmic solution
Sponsors:   Santen Inc.;   Vistakon Pharmaceuticals
Completed

Thu, 06 Mar 2008 12:00:00 EST

A Thorough QT/QTc Study to Assess the Effects of Androxal in Healthy Male Subjects

Condition:   Healthy
Interventions:   Drug: Androxal 25 mg capsules;   Drug: Androxal 250 Capsules;   Drug: Placebo Capsules;   Drug: Moxifloxacin 400 mg
Sponsor:   Repros Therapeutics Inc.
Completed

Mon, 21 Apr 2014 12:00:00 EDT

The Effect Of Lersivirine (UK-453,061) On Qt Intervals In Healthy Subjects

Condition:   Healthy Volunteers
Interventions:   Drug: Lersivirine;   Drug: Placebo;   Drug: Lersivirine (if necessary);   Drug: Moxifloxacin
Sponsor:   Pfizer
Completed

Fri, 10 Jul 2009 12:00:00 EDT

A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart Function

Condition:   Healthy
Interventions:   Drug: Lucerastat (Treatment A);   Other: Placebo;   Drug: Moxifloxacin;   Drug: Lucerastat (Treatment B);   Drug: Lucerastat (Treatment C)
Sponsor:   Idorsia Pharmaceuticals Ltd.
Completed

Wed, 06 Feb 2019 12:00:00 EST

Study to Investigate the Effect of Balovaptan on the QTC Interval in Healthy Subjects

Condition:   Healthy Volunteers
Interventions:   Drug: Balovaptan therapeutic dose Treatment A;   Drug: Balovaptan supra-therapeutic dose Treatment B;   Drug: Active control [moxifloxacin] on Day 2 Treatment C;   Drug: Active control [Moxifloxacin] on Day 15 Treatment D;   Drug: Placebo for Balovaptan Treatment C;   Drug: Placebo for Balovaptan Treatment D;   Drug: Placebo for Moxifloxacin Treatment A;   Drug: Placebo for Moxifloxacin Treatment B;   Drug: Moxifloxacin Treatment C;   Drug: Placebo for Moxifloxacin Treatment C;   Drug: Placebo for Moxifloxacin Treatment D;   Drug: Moxifloxacin Treatment D
Sponsor:   Hoffmann-La Roche
Completed

Thu, 17 Jan 2019 12:00:00 EST

A Study to Evaluate the Effect of JNJ-53718678 on the Cardiac Repolarization Interval in Healthy Adult Participants

Condition:   Healthy
Interventions:   Drug: JNJ-53718678, 2000 mg;   Drug: JNJ-53718678, 3000 mg;   Drug: JNJ-53718678, 4500 mg or Dose to be decided;   Drug: JNJ-53718678 500 mg;   Drug: JNJ-53718678 Placebo;   Drug: Moxifloxacin 400 mg;   Drug: Moxifloxacin Placebo
Sponsor:   Janssen Research & Development, LLC
Completed

Thu, 04 Oct 2018 12:00:00 EDT

Phase 1, QT/QTC Interval Study in Healthy Subjects

Condition:   Cystic Fibrosis
Interventions:   Drug: Lumacaftor;   Drug: Lumacaftor Placebo;   Drug: Ivacaftor;   Drug: Ivacaftor Placebo;   Drug: moxifloxacin hydrochloride
Sponsor:   Vertex Pharmaceuticals Incorporated
Completed

Mon, 29 Jul 2013 12:00:00 EDT

A Two-part, Single-dose, Randomized Study to Evaluate the Safety of Supra-therapeutic Doses of RO7033877 and to Investigate the Effect of RO7033877 on the QTc Interval

Condition:   Healthy Volunteer
Interventions:   Drug: Part 1: SAD RO7033877;   Drug: Part 1: SAD placebo;   Drug: Part 2: Treatment A, RO7033877;   Drug: Part 2: Treatment B, RO7033877;   Drug: Part 2: Treatment C, moxifloxacin;   Drug: Part 2: Treatment D, RO7033877 and moxifloxacin placebo
Sponsor:   Hoffmann-La Roche
Completed

Tue, 17 Jun 2014 12:00:00 EDT

Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease

Condition:   Parkinson's Disease
Interventions:   Drug: Rotigotine;   Other: Placebo;   Drug: Moxifloxacin infusion;   Other: Placebo infusion
Sponsor:   UCB Pharma
Completed

Wed, 15 Feb 2006 12:00:00 EST

A Study to Evaluate the Effects of Esketamine on Cardiac Repolarization in Healthy Participants

Condition:   Healthy
Interventions:   Drug: Intranasal Esketamine;   Drug: Intravenous Esketamine;   Drug: Moxifloxacin;   Drug: Oral Placebo;   Drug: Intravenous Placebo;   Drug: Intranasal Placebo
Sponsor:   Janssen Research & Development, LLC
Completed

Thu, 14 Apr 2016 12:00:00 EDT

The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori

Condition:   Helicobacter Infection
Interventions:   Procedure: H. pylori culture and antimicrobial susceptibility test;   Drug: 14 day PBMT group;   Drug: 14 day MEA group
Sponsor:   Seoul National University Bundang Hospital
Completed

Thu, 29 Jan 2015 12:00:00 EST

The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection

Condition:   Helicobacter Infection
Interventions:   Drug: 10 day sequential therapy (Esomeprazole, amoxicillin, clarithromycin, metronidazole);   Drug: 7 day tailored PPI triple therapy (clarithromycin-containing triple therapy);   Drug: 7 day moxifloxacin based triple therapy [Esomeprazole, Moxifloxacin, Amoxicillin];   Drug: 7 or 14 days tailored EBMT therapy group (bismuth quadruple therapy)
Sponsor:   Seoul National University Bundang Hospital
Recruiting

Fri, 27 Feb 2015 12:00:00 EST

The Efficacy of the 7 Days Tailored Therapy as 2nd Rescue Therapy for Eradication of H. Pylori Infection

Condition:   Helicobacter Infection
Interventions:   Procedure: H. pylori culture and antimicrobial susceptibility testing;   Drug: 14 days empirical bismuth quadruple therapy (Proton pump inhibitor);   Drug: Metronidazole;   Drug: Tetracycline;   Drug: tripotassium dicitrate bismuthate;   Drug: 7 days tailored therapy Proton Pump Inhibitor;   Drug: Moxifloxacin;   Drug: Amoxicillin
Sponsor:   Seoul National University Bundang Hospital
Recruiting

Tue, 10 Feb 2015 12:00:00 EST

Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity

Condition:   Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy
Intervention:   Drug: combined oral contraceptives
Sponsor:   University of Southern California
Completed

Mon, 30 Sep 2013 12:00:00 EDT

Smoking, Sex Hormones, and Pregnancy

Conditions:   Nicotine Dependence;   Contraception
Interventions:   Drug: Low-dose Progesterone;   Drug: High-dose Progesterone
Sponsor:   University of Minnesota
Completed

Thu, 14 Mar 2013 12:00:00 EDT

TMC435-TiDP16-C117: The Effect of TMC435 on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers

Condition:   Hepatitis C
Interventions:   Drug: TMC435;   Drug: Placebo for TMC435;   Drug: Moxifloxacin;   Drug: Placebo for moxifloxacin
Sponsor:   Tibotec Pharmaceuticals, Ireland
Completed

Tue, 04 Jan 2011 12:00:00 EST

The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB

Condition:   MDR-TB
Interventions:   Drug: Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline);   Drug: Moxifloxacin;   Drug: Clofazimine;   Drug: Ethambutol;   Drug: Pyrazinamide;   Drug: Isoniazid;   Drug: Prothionamide;   Drug: Kanamycin;   Drug: Levofloxacin;   Drug: Bedaquiline
Sponsors:   IUATLD, Inc;   Medical Research Council;   Institute of Tropical Medicine, Belgium;   Liverpool School of Tropical Medicine;   Rede TB
Active, not recruiting

Mon, 06 Apr 2015 12:00:00 EDT

Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers

Condition:   Healthy
Interventions:   Drug: cangrelor;   Drug: moxifloxacin;   Drug: placebo
Sponsor:   The Medicines Company
Completed

Wed, 18 Jun 2008 12:00:00 EDT

A Drug Interaction Study of Folic Acid and Oral Contraceptive Tablets Containing Norgestimate (NGM) /Ethinyl Estradiol (EE) in Healthy Women.

Conditions:   Drug Interactions;   Healthy;   Pharmacokinetics
Intervention:   Drug: Norgestimate; Ethinyl Estradiol; Folic acid
Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed

Thu, 03 Jul 2008 12:00:00 EDT

Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females

Condition:   Headache, Migraine
Interventions:   Drug: Erenumab;   Drug: Ethynil Estradiol/Norgestimate Oral Contraceptive
Sponsor:   Amgen
Completed

Tue, 07 Jun 2016 12:00:00 EDT

Combination Antibiotic Therapy Compared to Monotherapy in the Treatment of Acute COPD

Condition:   COPD Exacerbation Acute
Interventions:   Drug: Beta-Lactams;   Drug: Fluoroquinolone
Sponsor:   Haiphong University of Medicine and Pharmacy
Completed

Mon, 10 May 2021 12:00:00 EDT

Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis

Condition:   Tuberculosis
Interventions:   Drug: Rifampicin;   Drug: Isoniazid;   Drug: Pyrazinamide;   Drug: Kanamycin;   Drug: Moxifloxacin
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Korean Center for Disease Control and Prevention;   International Tuberculosis Research Center;   Novartis Institute for Tropical Medicine;   Asian Medical Center
Completed

Thu, 01 Jan 2009 12:00:00 EST

A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants

Condition:   Healthy
Interventions:   Drug: ODV Placebo (Matching 25 mg ODV);   Drug: ODV Placebo (Matching 200 mg ODV);   Drug: ODV Placebo (Matching 125 mg ODV);   Drug: ODV Placebo (Matching 100 mg ODV);   Drug: SMV Placebo (Matching 150 mg SMV);   Drug: AL-335 Placebo (matching 1200 mg AL-335);   Drug: Moxifloxacin Placebo (matching 400 mg moxifloxacin);   Drug: ODV 25 mg;   Drug: ODV 200 mg;   Drug: ODV 125 mg;   Drug: ODV 100 mg;   Drug: SMV 150 mg;   Drug: AL-335 1200 mg
Sponsor:   Janssen Research & Development, LLC
Completed

Tue, 16 May 2017 12:00:00 EDT

Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis

Condition:   Keratitis; Infectious Disease (Manifestation)
Interventions:   Device: PACK-CXL;   Drug: Cefazolin in combination with either tobramycin or gentamicin;   Drug: Cycloplegic agents (cyclopentolate 1% eye drops);   Drug: Fluoroquinolones (Besifloxacin ; ciprofloxacin ; gatifloxacin ; levofloxacin ; moxifloxacin ; ofloxacin );   Drug: Corticosteroids (prednisolone acetate 0.5% or 1% eye drops)
Sponsor:   University Hospital, Geneva
Completed

Thu, 24 Mar 2016 12:00:00 EDT

The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB

Condition:   Multi-drug Resistant Tuberculosis
Intervention:   Drug: 18-month regimen containing 6 anti-TB drugs
Sponsor:   Beijing Chest Hospital
Recruiting

Tue, 05 Feb 2019 12:00:00 EST

A Drug Interaction Study of Folic Acid and Oral Contraceptive Tablets Containing Norgestimate (NGM)/Ethinyl Estradiol (EE) in Healthy Women.

Conditions:   Drug Interactions;   Contraception;   Pharmacokinetics
Intervention:   Drug: Norgestimate; Ethinyl Estradiol; Folic acid
Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed

Thu, 03 Jul 2008 12:00:00 EDT

Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators

Condition:   Healthy
Interventions:   Drug: 1.5% levofloxacin ophthalmic solution;   Drug: 0.5% moxifloxacin hydrochloride ophthalmic solution;   Drug: 0.3% gatifloxacin ophthalmic solution
Sponsor:   Santen Inc.
Completed

Mon, 23 Jun 2008 12:00:00 EDT

Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects

Condition:   Healthy
Interventions:   Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882);   Drug: Moxifloxacin (BAY12-8039);   Drug: Placebo
Sponsor:   Bayer
Completed

Tue, 04 Apr 2006 12:00:00 EDT

Effect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac Repolarization

Condition:   Healthy Volunteers
Interventions:   Drug: Methylnaltrexone (MNTX);   Drug: Placebo;   Drug: Moxifloxacin
Sponsor:   Bausch Health Americas, Inc.
Completed

Wed, 01 Jun 2011 12:00:00 EDT

Essentiality of INH in TB Therapy

Condition:   Tuberculosis
Interventions:   Drug: Rifampicin;   Drug: Isoniazid;   Drug: Pyrazinamide;   Drug: Ethambutol;   Drug: Moxifloxacin
Sponsors:   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Completed

Wed, 02 May 2012 12:00:00 EDT

A Unique Regimen for Treatment of Helicobacter Pylori Infection

Condition:   Helicobacter Infections
Interventions:   Drug: Quadruple therapy;   Drug: Classic treatment
Sponsor:   Sherief Abd-Elsalam
Recruiting

Mon, 09 Apr 2018 12:00:00 EDT

Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis

Condition:   Osteomyelitis
Interventions:   Drug: Intravenous Antibacterial Agent;   Drug: Oral Antibacterial Agent
Sponsor:   Loyola University
Terminated

Fri, 20 Jun 2014 12:00:00 EDT

An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis

Conditions:   Tuberculosis;   Multidrug Resistant Tuberculosis;   Extensively-drug Resistant Tuberculosis
Interventions:   Drug: Linezolid;   Drug: Bedaquiline;   Drug: Levofloxacin;   Drug: Pyrazinamide;   Drug: Isoniazid;   Drug: Ethionamide;   Drug: Terizidone;   Drug: Moxifloxacin;   Drug: Kanamycin
Sponsors:   University of Cape Town;   University of Limpopo;   Walter Sisulu University;   University of Stellenbosch;   University of Cape Town Lung Institute
Completed

Wed, 27 May 2015 12:00:00 EDT

The Effect of Norgestimate/Ethinyl Estradiol on Bone Density in Pediatric Subjects With Anorexia Nervosa

Condition:   Osteoporosis
Intervention:   Drug: norgestimate/ethinyl estradiol
Sponsor:   McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Completed

Wed, 03 May 2006 12:00:00 EDT

Oral Contraceptive DDI Study

Condition:   Healthy
Interventions:   Drug: sotagliflozin;   Drug: oral contraceptive;   Drug: oral contraceptive + sotagliflozin
Sponsor:   Lexicon Pharmaceuticals
Unknown status

Fri, 10 Jul 2015 12:00:00 EDT

Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects

Condition:   Healthy
Interventions:   Drug: lomitapide;   Drug: EE/norgestimate
Sponsor:   Aegerion Pharmaceuticals, Inc.
Completed

Thu, 06 Mar 2014 12:00:00 EST

A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204

Condition:   Acne Vulgaris
Interventions:   Drug: SB204 4%;   Drug: SB204 8% or 12%;   Drug: Vehicle
Sponsors:   Novan, Inc.;   Spaulding Clinical Research LLC
Completed

Tue, 20 Oct 2015 12:00:00 EDT

An Open-Label Study Evaluating Breakthrough Bleeding and Spotting With Norgestimate/Ethinyl Estradiol Tablets Administered as an Extended Regimen

Condition:   Metrorrhagia
Intervention:   Drug: Norgestimate/Ethinyl Estradiol tablet
Sponsor:   McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Completed

Mon, 26 Jun 2006 12:00:00 EDT

Study to Evaluate Cycle Control With Norgestimate/Ethinyl Estradiol and Drospirenone/Ethinyl Estradiol in Healthy Sexually Active Females

Condition:   Contraception
Intervention:   Drug: Norgestimate/ethinyl estradiol; Drospirenone/ethinyl estradiol
Sponsor:   Ortho-McNeil Janssen Scientific Affairs, LLC
Completed

Wed, 03 Sep 2008 12:00:00 EDT

A Study of Efficacy and Safety With the Transdermal Contraceptive System.

Conditions:   Contraception;   Female Contraception
Intervention:   Drug: norelgestromin + ethinyl estradiol
Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed

Wed, 12 Oct 2005 12:00:00 EDT

Odiparcil QT Definitive Study

Conditions:   Fibrillation, Atrial;   Atrial Fibrillation
Intervention:   Drug: Odiparcil
Sponsor:   GlaxoSmithKline
Terminated

Mon, 19 Feb 2007 12:00:00 EST

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

Condition:   Pulmonary Disease Due to Mycobacteria (Diagnosis)
Interventions:   Drug: Amikacin;   Drug: Tigecycline;   Drug: Imipenem;   Drug: Cefoxitin;   Drug: Azithromycin;   Drug: Clarithromycin;   Drug: Clofazimine;   Drug: Ethambutol;   Drug: Linezolid;   Drug: co-trimoxazole;   Drug: Doxycycline;   Drug: Moxifloxacin;   Drug: Bedaquiline;   Drug: Rifabutin
Sponsors:   The University of Queensland;   Australian Government Department of Health and Ageing;   Children's Hospital Foundation;   Cystic Fibrosis Foundation;   Newcastle University;   Griffith University;   Erasmus Medical Center;   Monash University;   University of Copenhagen;   Hôpital Cochin;   South Australian Health and Medical Research Institute;   University of Melbourne;   James Cook University, Queensland, Australia;   Murdoch Childrens Research Institute
Recruiting

Tue, 17 Mar 2020 12:00:00 EDT

Study Evaluating the Effects of MOA-728 on Cardiac Repolarization in Healthy Subjects

Condition:   Healthy
Intervention:   Drug: MOA-728
Sponsor:   Bausch Health Americas, Inc.
Completed

Tue, 13 Feb 2007 12:00:00 EST

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Condition:   Community-acquired Pneumonia, Influenza, COVID-19
Interventions:   Drug: Fixed-duration Hydrocortisone;   Drug: Shock-dependent hydrocortisone;   Drug: Ceftriaxone;   Drug: Moxifloxacin or Levofloxacin;   Drug: Piperacillin-tazobactam;   Drug: Ceftaroline;   Drug: Amoxicillin-clavulanate;   Drug: Macrolide administered for 3-5 days;   Drug: Macrolide administered for up to 14 days;   Drug: Five-days oseltamivir;   Drug: Ten-days oseltamivir;   Drug: Lopinavir/ritonavir;   Drug: Hydroxychloroquine;   Drug: Hydroxychloroquine + lopinavir/ritonavir;   Drug: Interferon-β1a;   Drug: Anakinra;   Drug: Fixed-duration higher dose Hydrocortisone;   Drug: Tocilizumab;   Drug: Sarilumab;   Drug: Vitamin C;   Drug: Therapeutic anticoagulation;   Drug: Simvastatin;   Biological: Convalescent plasma;   Other: Protocolised mechanical ventilation strategy;   Drug: Eritoran;   Drug: Apremilast;   Drug: Aspirin;   Drug: Clopidogrel;   Drug: Prasugrel;   Drug: Ticagrelor
Sponsors:   MJM Bonten;   Australian and New Zealand Intensive Care Research Centre;   Medical Research Institute of New Zealand;   Unity Health;   Berry Consultants;   Global Coalition for Adaptive Research;   University of Pittsburgh Medical Center
Recruiting

Wed, 13 Apr 2016 12:00:00 EDT

Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects

Condition:   Cardiac Safety
Interventions:   Drug: telaglenastat;   Other: telaglenastat placebo;   Other: moxifloxicin
Sponsor:   Calithera Biosciences, Inc
Completed

Thu, 29 Oct 2020 12:00:00 EDT

Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema

Conditions:   Macular Edema, Cystoid;   Vision Disorders;   Diabetic Macular Edema;   Cystoid Macular Edema Following Cataract Surgery;   Cataract
Interventions:   Drug: Dexamethasone Drug delivery system (Ozurdex);   Procedure: Cataract surgery
Sponsor:   Postgraduate Institute of Medical Education and Research
Completed

Wed, 07 Mar 2012 12:00:00 EST

Feasibility of Centralized Therapeutic Drug Monitoring of Fluoroquinolones in Multi-Drug Resistant Tuberculosis Patients

Condition:   Tuberculosis, Multidrug-Resistant
Intervention:   Procedure: Centralized Therapeutic Drug Monitoring
Sponsor:   University Medical Center Groningen
Unknown status

Wed, 24 Jan 2018 12:00:00 EST

A Study of Danoprevir in Combination With Low-Dose Ritonavir in Healthy Subjects

Condition:   Healthy Volunteer
Interventions:   Drug: danoprevir;   Drug: danoprevir placebo;   Drug: moxifloxacin;   Drug: moxifloxacin placebo;   Drug: ritonavir;   Drug: ritonavir placebo
Sponsor:   Hoffmann-La Roche
Completed

Wed, 20 Jul 2011 12:00:00 EDT

Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol

Condition:   HCV Infection
Interventions:   Drug: SOF/VEL/VOX;   Drug: VOX;   Drug: Norgestimate/ethinyl estradiol
Sponsor:   Gilead Sciences
Completed

Wed, 26 Aug 2015 12:00:00 EDT

A Randomized, Single-Dose, Comparative, Positive and Placebo Controlled, Four-Way, Four Period, Cross-Over Study to Evaluate the Effect of DIC075V on QTc Intervals in Healthy Subjects

Condition:   Ventricular Repolarization
Intervention:   Drug: DIC075V
Sponsor:   Hospira, now a wholly owned subsidiary of Pfizer
Completed

Mon, 18 Mar 2013 12:00:00 EDT

An Observational Study of Oral Fluoroquinolones and the Risk of Retinal Detachment

Condition:   Retinal Detachment
Intervention:  
Sponsor:   Janssen Research & Development, LLC
Completed

Wed, 19 Jun 2013 12:00:00 EDT

Effects of Advair® in Outpatients With Chronic Obstructive Pulmonary Disease (COPD) Acute Exacerbation

Condition:   Chronic Obstructive Pulmonary Disease (COPD)
Interventions:   Drug: prednisone group;   Drug: Advair group
Sponsors:   Laval University;   GlaxoSmithKline
Completed

Wed, 19 Sep 2007 12:00:00 EDT

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Condition:   HIV Infections
Interventions:   Drug: atazanavir/cobicistat;   Drug: darunavir/ritonavir;   Drug: darunavir/cobicistat;   Drug: etravirine;   Drug: elvitegravir/cobicistat;   Drug: dolutegravir;   Drug: tenofovir alafenamide fumarate (TAF);   Drug: TAF/cobicistat;   Drug: TAF/ritonavir;   Drug: efavirenz;   Drug: lopinavir/ritonavir;   Drug: nevirapine;   Drug: rifampicin;   Drug: ethambutol;   Drug: isoniazid;   Drug: pyrazinamide;   Drug: kanamycin;   Drug: amikacin;   Drug: capreomycin;   Drug: moxifloxacin;   Drug: levofloxacin;   Drug: ofloxacin;   Drug: ethionamide/prothionamide;   Drug: terizidone/cycloserine;   Drug: para-aminosalicylic acid (PAS);   Drug: high dose isoniazid (INH);   Drug: bedaquiline;   Drug: clofazamine;   Drug: delamanid;   Drug: linezolid;   Drug: pretomanid;   Drug: atazanavir/ritonavir/tenofovir;   Drug: ethinyl estradiol oral contraceptive;   Drug: etonogestrel implant
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Completed

Thu, 01 Aug 2002 12:00:00 EDT

NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB

Condition:   Multidrug Resistant Tuberculosis
Interventions:   Drug: WHO-approved MDR-TB regimen;   Drug: NGS-guided regimen: Regimen A;   Drug: NGS-guided regimen: Regimen B;   Drug: NGS-guided regimen: Regimen C
Sponsor:   Huashan Hospital
Not yet recruiting

Mon, 30 Jul 2018 12:00:00 EDT

Elagolix for Fertility Enhancement Clinical Trial

Conditions:   Endometriosis;   Unexplained Infertility
Interventions:   Drug: Elagolix;   Drug: Oral Contraceptive
Sponsors:   Wake Forest University Health Sciences;   University of North Carolina, Chapel Hill;   Stanford University
Not yet recruiting

Wed, 31 Jul 2019 12:00:00 EDT

A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo and Positive Controlled Study to Evaluate the Cardiovascular Effect of Tetrodotoxin in Healthy Adult Subjects

Condition:   TQT Study
Interventions:   Drug: Tetrodotoxin;   Drug: Placebos
Sponsors:   Wex Pharmaceuticals Inc.;   Celerion
Completed

Tue, 10 Sep 2019 12:00:00 EDT

Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan

Condition:   Multidrug Resistant Tuberculosis
Intervention:   Drug: Short course MDR-TB treatment regimen
Sponsors:   Medecins Sans Frontieres, Netherlands;   Ministry of Health, Republic of Uzbekistan;   Imperial College London
Unknown status

Tue, 14 Jul 2015 12:00:00 EDT

A Study to Evaluate How VI-0521 Affect Cardiac Repolarization in Healthy Male and Female Volunteers

Condition:   Torsades de Pointes
Intervention:   Drug: VI-0521
Sponsor:   VIVUS, Inc.
Completed

Tue, 10 Feb 2009 12:00:00 EST

An Epidemiological Survey to Establish the Spectrum of Circulating Serotypes of S. Pneumoniae, in Patients Older 18 Years

Conditions:   Pneumonia, Pneumococcal;   Invasive Pneumococcal Disease;   Acute Otitis Media
Intervention:   Other: Detection of Streptococcus pneumoniae strains
Sponsor:   The Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC)
Completed

Thu, 09 Jul 2020 12:00:00 EDT

Pharmacokinetics of Drugs Administered to Children

Condition:   Pediatric ALL
Intervention:   Drug: Standard of care drug
Sponsor:   Duke University
Recruiting

Thu, 29 Mar 2018 12:00:00 EDT

Effectiveness of Corneal Accelerated Crosslinking for Infectious Keratitis

Condition:   Keratitis
Intervention:   Procedure: Accelerated Corneal Cross-linking
Sponsors:   Instituto de Oftalmología Fundación Conde de Valenciana;   Asociación para Evitar la Ceguera en México
Unknown status

Mon, 15 Aug 2016 12:00:00 EDT

The Individualized M(X) Drug-resistant TB Treatment Strategy Study

Condition:   Tuberculosis, Multidrug-Resistant
Interventions:   Drug: Individualized TB treatment with multiple drugs;   Drug: Standardized TB treatment with multiple drugs
Sponsor:   Centre for the AIDS Programme of Research in South Africa
Recruiting

Wed, 02 Aug 2017 12:00:00 EDT

Strategy for Early Treatment of Exacerbations in COPD: Standing Prescriptions of Advair With a Written Action Plan in the Event of an Exacerbation

Conditions:   COPD;   Chronic Obstructive Pulmonary Disease
Interventions:   Drug: Double dose of Salmeterol + Fluticasone Propionate;   Behavioral: Self-management education on the use of a self-administered prescription for exacerbation.;   Drug: Self-administered prescription
Sponsors:   McGill University Health Centre/Research Institute of the McGill University Health Centre;   GlaxoSmithKline
Completed

Tue, 13 May 2014 12:00:00 EDT

Rapamune Improves Outcomes of Severe H1N1 Pneumonia

Conditions:   H1N1 Pneumonia;   Hypoxemia
Intervention:   Drug: Sirolimus (Rapamune 2mg/day, Pfizer)
Sponsor:   Chang Gung Memorial Hospital
Completed

Fri, 15 Jun 2012 12:00:00 EDT

Economic Impact of Dropless Therapy Versus Usual Care for Cataract Surgery: A Real-World Study.

Condition:   Cataract Surgery
Interventions:   Combination Product: Dropless Therapy;   Drug: Usual Care
Sponsors:   PeriPharm;   Advance Dosage Forms, Inc.;   Imprimis Pharmaceuticals, Inc.
Terminated

Tue, 21 Aug 2018 12:00:00 EDT

Endothelial Cell Loss After Penetrating Keratoplasty

Condition:   Keratoconus
Intervention:   Procedure: PKP
Sponsor:   Alexandria University
Completed

Tue, 07 Jul 2020 12:00:00 EDT

Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)

Condition:   Multidrug Resistant Tuberculosis
Interventions:   Drug: PZA sensitivity guided ultra-short all Oral Regimen;   Drug: Standardized Shorter Regimen
Sponsor:   Huashan Hospital
Recruiting

Thu, 07 Mar 2019 12:00:00 EST

Evaluating Newly Approved Drugs for Multidrug-resistant TB

Conditions:   Tuberculosis, Multidrug-Resistant;   Infection, Bacterial;   Pulmonary Tuberculoses
Interventions:   Drug: Bedaquiline;   Drug: Delamanid;   Drug: Clofazimine;   Drug: Levofloxacin;   Drug: Moxifloxacin;   Drug: Linezolid;   Drug: Pyrazinamide;   Drug: Control arm MDR-TB regimen, consistent with WHO guidelines
Sponsors:   Médecins Sans Frontières, France;   Partners in Health;   Harvard Medical School;   Epicentre;   Institute of Tropical Medicine, Belgium;   Socios En Salud, Peru;   Interactive Research and Development
Recruiting

Thu, 28 Apr 2016 12:00:00 EDT

Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)

Conditions:   Keratoconus;   Ectasia;   Degeneration
Intervention:  
Sponsor:   Cxlusa
Terminated

Thu, 01 Apr 2010 12:00:00 EDT

Randomized Controlled Multi-center Short Course Treatment for Rifampicin Resistant Tuberculosis

Condition:   Tuberculosis
Intervention:   Drug: Total oral short-term therapy that includes linezolid, bedaquiline and/or cycloserine.
Sponsor:   Beijing Chest Hospital
Recruiting

Fri, 11 Sep 2020 12:00:00 EDT

A 6-month Observational Study on the Influence of Combined Oral Contraceptive vs. Levonorgestrel Intrauterine Device on Body Weight in Pre-Menopausal Women With Overweight or Obesity

Conditions:   Contraceptive Usage;   Overweight or Obesity;   Body Weight Changes;   Appetitive Behavior;   Eating Behavior
Intervention:  
Sponsor:   University of Colorado, Denver
Not yet recruiting

Wed, 29 Sep 2021 12:00:00 EDT

Ocular-hypertensive Response to Topical Steroids in Children After Bilateral Strabismus Surgery

Condition:   Intraocular Pressure
Interventions:   Drug: 0.1 % Dexamethasone;   Drug: 0.1% Fluorometholone;   Drug: 1% Rimexolone
Sponsor:   Cairo University
Completed

Wed, 29 Jun 2016 12:00:00 EDT

Patients Response to Early Switch To Oral:Osteomyelitis Study

Condition:   Osteomyelitis
Interventions:   Drug: oral antibiotics;   Procedure: intravenous antibiotics
Sponsors:   Julio Ramirez;   University of Louisville
Terminated

Fri, 28 Mar 2014 12:00:00 EDT

Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis

Condition:   Tuberculosis
Intervention:   Drug: anti-tuberculosis drug
Sponsors:   Beijing Children's Hospital;   Shandong University;   Robert Debré Hospital;   Rennes University Hospital
Recruiting

Fri, 10 Aug 2018 12:00:00 EDT

Inpatient Adolescent Contraception

Conditions:   Pregnancy Related;   Contraception;   Contraceptive Usage;   Contraception Behavior;   Pregnancy
Interventions:   Behavioral: SexHealth II;   Drug: Contraceptive
Sponsor:   Children's Mercy Hospital Kansas City
Recruiting

Tue, 09 Jun 2020 12:00:00 EDT

Effects of Teduglutide on Cardiac Repolarisation and Conduction in Healthy Male and Female Volunteers

Condition:   Healthy
Intervention:   Drug: Teduglutide
Sponsor:   Nycomed
Completed

Wed, 09 Dec 2009 12:00:00 EST

Study of Leptin for the Treatment of Hypothalamic Amenorrhea

Condition:   Amenorrhea
Interventions:   Drug: r-metHuLeptin;   Drug: Oral Contraceptive Pills (OCPs);   Other: Placebo
Sponsors:   Beth Israel Deaconess Medical Center;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Center for Research Resources (NCRR);   Amgen
Completed

Mon, 15 Aug 2005 12:00:00 EDT

Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections

Conditions:   Pneumonia;   Acute Exacerbation of Chronic Obstructive Airways Disease
Interventions:   Other: PCT-level;   Behavioral: Antibiotic treatment based on PCT-level
Sponsors:   Holbaek Sygehus;   Region Sjælland;   Aase and Ejnar Danielsens Foundation
Unknown status

Tue, 24 Jun 2014 12:00:00 EDT

Treatment of Keratoconus With PALK Versus PK

Condition:   Keratoconus
Interventions:   Procedure: Penetrating keratoplasty;   Procedure: Pachymetry and Excimer laser assisted lamellar keratoplasty;   Drug: Treatment posterior to surgery
Sponsor:   Instituto de Oftalmología Fundación Conde de Valenciana
Completed

Wed, 09 Dec 2015 12:00:00 EST

Community-Acquired Pneumonia - Study on the Initial Treatment With Antibiotics of Lower Respiratory Tract Infections

Condition:   Community-acquired Pneumonia
Intervention:   Other: Preferred empirical treatment
Sponsors:   UMC Utrecht;   ZonMw: The Netherlands Organisation for Health Research and Development
Completed

Wed, 08 Aug 2012 12:00:00 EDT

Fluoroquinolone Associated Disability

Conditions:   Bronchitis;   Sinusitis;   Urinary Tract Infections
Interventions:   Drug: Fluoroquinolone (FQ);   Drug: Azithromycin (AZ);   Drug: Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination
Sponsor:   Janssen Research & Development, LLC
Completed

Thu, 24 May 2018 12:00:00 EDT

A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events

Conditions:   Retinal Detachment;   Achilles Tendon;   Aneurysm, Dissecting
Interventions:   Drug: Oral Fluoroquinolones (FQ);   Drug: Other Antibiotics;   Other: Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure
Sponsor:   Janssen Research & Development, LLC
Completed

Tue, 27 Mar 2018 12:00:00 EDT

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

Conditions:   HIV Infections;   Tuberculosis
Interventions:   Drug: Bictegravir (BIC);   Drug: Tenofovir alafenamide (TAF);   Drug: Cabotegravir (CAB);   Drug: Dolutegravir (DTG);   Drug: Atazanavir/ritonavir (ATV/r);   Drug: Darunavir/ritonavir (DRV/r);   Drug: Lopinavir/ritonavir (LPV/r);   Drug: Cobicistat;   Drug: Ritonavir;   Drug: First-Line TB Treatment;   Drug: Second-Line TB Treatment;   Drug: Doravirine (DOR)
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Institute of Mental Health (NIMH);   Gilead Sciences;   ViiV Healthcare;   Merck Sharp & Dohme Corp.
Recruiting

Wed, 19 Aug 2020 12:00:00 EDT

Premature Discontinuation of Contraceptive Implants

Condition:   Contraception Behavior
Intervention:   Drug: Ethinyl Estradiol / Norgestimate Oral Tablet
Sponsor:   University of Colorado, Denver
Recruiting

Fri, 02 Apr 2021 12:00:00 EDT

Antibiotic Resistant Patterns of Conjunctival and Nasophayngeal Flora After Repeated Exposure to Topical Antibiotics

Condition:   Age-related Macular Degeneration
Intervention:   Procedure: Conjunctival and nasopharyngeal bacteria cultures
Sponsor:   Vanderbilt University
Completed

Thu, 29 Jan 2009 12:00:00 EST

Impact of Ceftriaxone and/or Fluoroquinolone (FQ) Treatment on the Gut Microbiota of Hospitalized Patients.

Condition:   Bacterial Infections
Intervention:  
Sponsor:   Assistance Publique - Hôpitaux de Paris
Terminated

Thu, 09 Jan 2014 12:00:00 EST

A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban

Condition:   Embryo Transfer
Interventions:   Drug: Epelsiban;   Drug: Placebo;   Drug: Oxytocin;   Drug: Ortho-Cylcen (21)® tablet
Sponsor:   GlaxoSmithKline
Terminated

Mon, 11 Aug 2014 12:00:00 EDT

Bioequivalence Study of the Oral Contraceptive (OC) Tablet Containing Norgestimate (NGM)/Ethinyl Estradiol (EE) With or Without Folic Acid in Healthy Women.

Conditions:   Pharmacokinetics;   Therapeutic Equivalency;   Contraceptives, Oral
Intervention:   Drug: Norgestimate; Ethinyl Estradiol; Folic acid.
Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed

Thu, 03 Jul 2008 12:00:00 EDT

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery

Conditions:   Corneal Edema;   Corneal Defect;   Corneal Transplant;   Penetrating KeratoPlasty;   Anterior Chamber Inflammation;   Ocular Pain
Interventions:   Drug: Dextenza 0.4Mg Ophthalmic Insert;   Drug: Prednisolone Acetate 1% Oph Susp
Sponsor:   Nicole Fram M.D.
Recruiting

Thu, 20 Aug 2020 12:00:00 EDT

Bioequivalence Study of the Oral Contraceptive Tablet Containing Norgestimate (NGM)/Ethinyl Estradiol (EE) With or Without Folic Acid in Healthy Women.

Conditions:   Female Contraception;   Contraception;   Therapeutic Equivalency;   Pharmacokinetics
Intervention:   Drug: Norgestimate/Ehinyl Estradiol; Folic acid.
Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed

Thu, 03 Jul 2008 12:00:00 EDT

An Efficacy and Safety Study Comparing Oral Contraceptive Containing Norgestimate or Desogestrel for Acne Treatment

Condition:   Acne Vulgaris
Interventions:   Drug: Ethinyl estradiol/Norgestimate (EE/NGM);   Drug: Ethinyl estradiol/Desogestrel (EE/DSG)
Sponsor:   Janssen-Cilag Ltd.,Thailand
Completed

Tue, 08 Nov 2011 12:00:00 EST